## NCCN Guidelines Version 3.2014 Panel Members

### Ovarian Cancer

**Discussion**

- **Robert J. Morgan, Jr., MD/Chair ‡**
  City of Hope Comprehensive Cancer Center

- **Deborah K. Armstrong, MD/Vice Chair †**
  The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

- **Ronald D. Alvarez, MD Ω**
  University of Alabama at Birmingham Comprehensive Cancer Center

- **Lee-may Chen, MD Ω**
  UCSF Helen Diller Family Comprehensive Cancer Center

- **Larry Copeland, MD Ω**
  The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

- **Marta Ann Crispens, MD Ω**
  Vanderbilt-Ingram Cancer Center

- **David M. Gershenson, MD Ω**
  The University of Texas MD Anderson Cancer Center

- **Heidi J. Gray, MD Ω**
  University of Washington Medical Center/Seattle Cancer Care Alliance

- **Ardeshir Hakam, MD ≠**
  Moffitt Cancer Center

- **Laura J. Havrilesky, MD Ω**
  Duke Cancer Institute

- **Carolyn Johnston, MD Ω**
  University of Michigan Comprehensive Cancer Center

- **Shashikant Lele, MD Ω**
  Roswell Park Cancer Institute

- **Lainie Martin, MD †**
  Fox Chase Cancer Center

- **Ursula A. Matulonis, MD †**
  Dana-Farber/Brigham and Women’s Cancer Center

- **David M. O’Malley, MD Ω**
  The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

- **Richard T. Penson, MD, MRCP †**
  Massachusetts General Hospital Cancer Center

- **Steven C. Plaxe, MD Ω**
  UC San Diego Moores Cancer Center

- **Matthew A. Powell, MD Ω**
  Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

- **Steven W. Remmenga, MD Ω**
  Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center

- **Paul Sabbatini, MD † ♦**
  Memorial Sloan-Kettering Cancer Center

- **Joseph T. Santoso, MD Ω**
  St. Jude Children’s Research Hospital/University of Tennessee Health Science Center

- **Monique Spillman, MD, PhD Ω**
  University of Colorado Cancer Center

- **Nelson Teng, MD, PhD Ω**
  Stanford Cancer Institute

- **Theresa L. Werner, MD † ‡**
  Huntsman Cancer Institute at the University of Utah

**NCCN**

Jennifer Burns
Miranda Hughes, PhD

---

Ω Gynecology oncology
‡ Hematology/Hematology oncology
† Medical oncology
♦ Internal medicine
≠ Pathology
* Discussion writing committee member
Clinical Trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/physician.html.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise specified. See NCCN Categories of Evidence and Consensus.

NCCN Guidelines for Patients® are available at www.nccn.org/patients.

Staging (ST-1)
NCCN Guidelines Version 3.2014 Updates
Ovarian Cancer

Updates to Version 3.2014 of the NCCN Guidelines for Ovarian Cancer from Version 2.2014 include:

**OV-D 1 of 2**
- The following combination therapies were added to the preferred list for platinum-resistant disease:
  - Liposomal doxorubicin/bevacizumab
  - Paclitaxel (weekly)/bevacizumab
  - Topotecan/bevacizumab
- Footnote "e" was added: Contraindicated for patients at increased risk of gastrointestinal perforation.

**OV-D 2 of 2**
- MS-1
  - The discussion was updated to reflect the algorithm changes.

Updates to Version 2.2014 of the NCCN Guidelines for Ovarian Cancer from Version 1.2014 include:

**OV-D 2 of 2**
- References were added:
- MS-1
  - The discussion was updated to reflect the algorithm changes.

Updates to Version 1.2014 of the NCCN Guidelines for Ovarian Cancer from Version 2.2013 include:

**OV-1 (continued)**
- Diagnosis by previous surgery, Workup
  - First bullet, “Obtain family history and consider family history evaluation” was revised and split into two bullets as follows:
    - “Obtain family history.”
    - “Refer for family history genetic risk evaluation.”
  - Sixth bullet was modified: “Ultrasound and/or abdominal/pelvic CT/MRI as clinically indicated.”
- Footnote “c” was added: “See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian and NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal.”
- Footnote “d” was added: “Primary treatment should not be delayed for a genetic counseling referral.”
- Footnote “g” was added: “For rare tumors including clear cell, mucinous, or low grade, see Discussion.”

**OV-2**
- Incomplete previous surgery and/or staging, #6 was added: “Occult invasive carcinoma found at time of risk reduction surgery.”

Continued on next page
Updates to Version 1.2014 of the NCCN Guidelines for Ovarian Cancer from Version 2.2013 include:

**OV-4**
- Secondary adjuvant therapy, “postremission paclitaxel” was changed from a category 2B to a category 3 recommendation.

**OV-5**
- Monitoring/follow-up, fourth bullet was revised: “Consider family history-evaluation Refer for genetic risk evaluation, if not previously done.”

**OV-A**
- This section was revised significantly.
- “Principles of Primary Surgery” was changed to “Principles of Surgery.”

**OV-B 1 of 3**
- General, second bullet was added: “Prior to the initiation of any therapy:
  - Patients of child-bearing potential who desire fertility-sparing procedures should be referred to an appropriate fertility specialist. (See NCCN Guidelines for Adolescent and Young Adult Oncology)
  - Goals of systemic therapy should be discussed.

**OV-B 2 of 3**
- Section was added: “For elderly patients (>age 65) and/or those with comorbidities.”
- Section was added: “Definitions used in the NCCN Guidelines for Ovarian Cancer.”

**OV-B 3 of 3**
- Regimens were reordered and labels were added for:
  - Intraperitoneal (IP)/Intravenous (IV) Regimen, and
  - Intravenous (IV) Regimens
- Under IV Regimens, last sub-bullet was modified: “Paclitaxel 175 mg/m² IV over 3 hours, carboplatin AUC 5-6 IV over 1 hour...”
- Footnote “2” was added: “IV regimens may be considered for neoadjuvant therapy.”

**OV-C 4 of 7**
- After management/treatment for second or further exposure, first bullet was revised: “Consider allergy consultation.”, if possible.”

**OV-C 5 of 7**
- After management/treatment for severe reaction, first bullet was revised: “Consider allergy consultation.”, if possible.”

**OV-D 1 of 2**
- Other potentially active agents, doxorubicin was added to the list of single agent cytotoxic therapies.

---

**Less Common Ovarian Histopathologies**

**LCOH-1**
- “Ovarian low malignant potential tumors (borderline epithelial ovarian tumors)” was added under Diagnosis.

**LCOH-2**
- Footnote “b” was added: “Surgical principles for pediatric/young adult patients may differ from those for adult patients. See Principles of Surgery (OV-A).”

**LCOH-3**
- Footnote “d” was added: “Pediatric/young adult patients with the following clinical presentations may consider observation or chemotherapy as treatment options: Stage IA, IB dysgerminoma; stage IA, grade 1 immature teratoma; stage IA embryonal tumors; or stage IA yolk sac tumors.”

**LCOH-6**
- Footnote “n” was added: “Chemotherapy (IV or IP) has not been shown to be beneficial in ovarian low malignant potential tumors (borderline epithelial ovarian tumors).” (Also for LCOH-7 and LCOH-8)

**LCOH-7**
- After diagnosis of LMP tumor with institutional pathology review, “Incomplete surgical staging” was revised and split into two pathways:
  - “Residual disease remaining after first procedure.”
  - “No residual disease remaining after first procedure.”
  
- “Observe” was added after this pathway.

**ST-1**
# Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

## Clinical Presentation

Suspicious\(^a\)/palpable pelvic mass detected on abdominal/pelvic exam and/or ascites, abdominal distention, and/or symptoms such as bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, or urinary symptoms (urgency or frequency)\(^b\) without other obvious source of malignancy

## Workup

- Obtain family history\(^c\)
- Refer for genetic risk evaluation\(^c,d\)
- Abdominal/pelvic exam
- Chest imaging
- Complete blood count (CBC), chemistry profile with liver function test (LFT)
- GI examination as clinically indicated
- Ultrasound and/or abdominal/pelvic CT/MRI as clinically indicated\(^e\)
- CA-125 or other tumor markers as clinically indicated\(^f\)

Diagnosis by previous surgery or tissue biopsy (cytopathology)

- Obtain family history\(^c\)
- Refer for genetic risk evaluation\(^c,d\)
- Chest imaging
- CBC, chemistry profile with LFTs
- Institutional pathology review
- Ultrasound and/or abdominal/pelvic CT/MRI as clinically indicated\(^e\)
- CA-125 or other tumor markers as clinically indicated\(^f\)

## Primary Treatment\(^g,h,i,j\)

- Laparotomy/total abdominal hysterectomy (TAH)/ bilateral salpingo-oophorectomy (BSO) with comprehensive staging\(^i\) or unilateral salpingo-oophorectomy (USO) (clinical stage 1A or 1C, all grades with comprehensive staging if patient desires fertility) or
- Cytoreductive surgery\(^j\) if clinical stage II, III, or IV or
- Consider neoadjuvant chemotherapy\(^k\) (category 1)/primary interval cytoreduction\(^h\) (diagnosis by fine needle aspiration [FNA], biopsy, or paracentesis) for patients with bulky stage III/IV who are poor surgical candidates due to high-risk comorbidity conditions or disease factors

---


\(^c\)See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian and NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal.

\(^d\)Primary treatment should not be delayed for a genetic counseling referral.

\(^e\)PET/CT scan or MRI may be indicated for indeterminate lesions if results will alter management.

\(^f\)See Discussion for usefulness of diagnostic tests.

\(^g\)For rare tumors including clear cell, mucinous, or low grade, see Discussion.

\(^h\)Standard recommendation includes a patient evaluation by a gynecologic oncologist prior to initiating chemotherapy. Published data demonstrate that primary assessment and debulking by a gynecologic oncologist result in a survival advantage. Patients being evaluated for neoadjuvant chemotherapy should be seen by a fellowship-trained gynecologic oncologist prior to being considered a poor surgical candidate.

\(^i\)All women undergoing surgery for ovarian cancer should be counseled about the clinical benefit associated with combined IV and IP chemotherapy administration prior to surgery. NCI Clinical Announcement.

\(^j\)See Principles of Surgery (OV-A).

\(^k\)See Principles of Chemotherapy (OV-B) and Management of Drug Reactions (OV-C).
**DIAGNOSIS BY PREVIOUS SURGERY**

**Findings**

- Suspected stage IA or IB, grade 1
  - If observation considered: Surgical staging
  - If no residual disease: Surgical staging

- Suspected stage IA or IB, grade 2
  - Suspect residual disease: Completion surgery/surgical staging
  - Suspect no residual disease: Chemotherapy for 6 cycles or completion surgery/surgical staging

- Suspected stage IA or IB, grade 3 or clear cell or stage IC
  - Suspect residual disease: Completion surgery/surgical staging
  - Suspect no residual disease: Chemotherapy for 6 cycles or completion surgery/surgical staging

- Stage II, III, IV
  - Suspect potentially resectable residual disease: Tumor reductive surgery
  - Suspect unresectable residual disease: Chemotherapy for a total of 6-8 cycles
    - Consider completion surgery after 3-6 cycles followed by postoperative chemotherapy

**Primary Treatment**

- Surgical staging
- Completion surgery/surgical staging
- Chemotherapy for 6 cycles or completion surgery/surgical staging
- Tumor reductive surgery
- Chemotherapy for a total of 6-8 cycles

**Notes:**

- Standard recommendation includes a patient evaluation by a gynecologic oncologist prior to initiating chemotherapy. Published data demonstrate that primary assessment and debulking by a gynecologic oncologist result in a survival advantage. Patients being evaluated for neoadjuvant chemotherapy should be seen by a fellowship-trained gynecologic oncologist prior to being considered a poor nonsurgical candidate.

- See Principles of Surgery (OV-A), Principles of Chemotherapy (OV-B) and Management of Drug Reactions (OV-C).

- Based on clinical judgement of gynecologic oncologist, surgery may be performed after 6 cycles.

- *Note:* All recommendations are category 2A unless otherwise indicated.

- Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PATHOLOGIC STAGING

Stage IA or IB

<table>
<thead>
<tr>
<th>Grade 1</th>
<th>Observe</th>
<th>Intravenous (IV) taxane/carboplatin(k) for 3-6 cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 2</td>
<td>Observe or</td>
<td>IV taxane/carboplatin(k) for 3-6 cycles</td>
</tr>
<tr>
<td>Grade 3 or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>clear cell</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Stage IC

<table>
<thead>
<tr>
<th>Grade 1, 2, or 3</th>
<th>IV taxane/carboplatin(k) for 3-6 cycles</th>
</tr>
</thead>
</table>

Stage II

Stage III

Stage IV

<table>
<thead>
<tr>
<th>• Chemotherapy(n)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(i,k) in &lt;1 cm</td>
<td>optimally debulked stage II and stage III patients (category 1 for stage III)</td>
</tr>
<tr>
<td></td>
<td>or</td>
</tr>
<tr>
<td>(i) in &lt;1 cm</td>
<td>Intravenous taxane/carboplatin(k) for a total of 6-8 cycles (category 1)</td>
</tr>
<tr>
<td></td>
<td>• Completion surgery as indicated by tumor response and potential resectability in selected patients(j)</td>
</tr>
</tbody>
</table>

\(i\)All women undergoing surgery for ovarian cancer should be counseled about the clinical benefit associated with combined IV and IP chemotherapy administration prior to surgery. **NCI Clinical Announcement.**

\(j\)See **Principles of Surgery (OV-A).**

\(k\)See **Principles of Chemotherapy (OV-B) and Management of Drug Reactions (OV-C).**

\(m\)Patients receiving primary chemotherapy will be monitored as follows:

1. Pelvic exams at least every 2-3 cycles
2. Interim CBC with platelets as indicated
3. Chemistry profiles if indicated
4. CA-125 levels or other tumor markers as clinically indicated prior to each cycle of chemotherapy
5. Radiographic imaging if indicated

\(n\)See specific regimens on **Primary Chemotherapy/Primary Adjuvant Therapy Regimens for Stage II-IV (OV-B 3 of 3).**

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
STAGE II, III, IV
POST PRIMARY TREATMENT

SECONDARY ADJUVANT THERAPY

Stage II, III, IV
post-primary
treatment

Complete clinical remission

Partial remission
or progression

Clinical trial or
Observe or
Postremission paclitaxel (category 3)

See Monitoring/
Follow-Up (OV-5)

See Persistent Disease or
Recurrence Therapy (OV-6)

STAGE II, III, IV
POST PRIMARY TREATMENT

No objective evidence of disease (ie, negative physical exam, negative CA-125, negative CT with <1 cm lymph nodes).

See Discussion for dosing.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
STAGE I-IV COMPLETE RESPONSE

MONITORING/FOLLOW-UP

- Visits every 2-4 mo for 2 y, then 3-6 mo for 3 y, then annually after 5 y
- Physical exam including pelvic exam
- CA-125 or other tumor markers every visit if initially elevated
- Refer for genetic risk evaluation, if not previously done
- CBC and chemistry profile as indicated
- Chest/abdominal/pelvic CT, MRI, PET-CT, or PET (category 2B for PET) as clinically indicated
- Chest x-ray as indicated

RECURRENT DISEASE

- Rising CA-125, no previous chemotherapy or Clinical relapse, no previous chemotherapy
- Imaging studies: Chest/abdominal/pelvic CT, MRI, PET-CT, or PET (category 2B for PET) as clinically indicated

See Primary Treatment (OV-1)

- Clinical relapse, previous chemotherapy
- Imaging studies: Chest/abdominal/pelvic CT, MRI, PET-CT, or PET (category 2B for PET) as clinically indicated

See Therapy for Persistent Disease or Recurrence (OV-6)

- Serially rising CA-125, previous chemotherapy
- Imaging studies: Chest/abdominal/pelvic CT, MRI, PET-CT, or PET (category 2B for PET) as clinically indicated

Delay treatment until clinical relapse or Immediate treatment for recurrent disease (category 2B) or Clinical trial

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian and NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal.

There are data regarding the utility of CA-125 for monitoring of ovarian cancer after completion of primary therapy. See The Society of Gynecologic Oncology (SGO) position statement and Discussion.
Epithelial Ovarian Cancer/ Fallopian Tube Cancer/
Primary Peritoneal Cancer

DISEASE STATUS

Progression, stable, or persistent disease on primary chemotherapy

Complete remission and relapse <6 mo after stopping chemotherapy
or
Stage II, III, and IV with partial response

Complete remission and relapse ≥6 mo after stopping chemotherapy

Biochemical relapse (rising CA-125 and no radiographic evidence of disease)

Radiographic and/or clinical relapse

THERAPY FOR PERSISTENT DISEASE OR RECURRENCE\(^r,s,t\)

Clinical trial\(^d\)
or
Supportive/palliative care only
(See NCCN Guidelines for Palliative Care)
or
Recurrence therapy\(^r,t\)

Clinical trial\(^d\)
or
Recurrence therapy\(^r,t\)
or
Observe (category 2B)

Consider secondary cytoreductive surgery\(^j\)

Clinical trial\(^d\)
or
Combination platinum-based chemotherapy\(^r,t\)
pREFERRED FOR FIRST RECURRENCE (CATEGORY 1)
or
Recurrence therapy\(^r,t\)

Clinical trial\(^d\)
or
Delay treatment until clinical relapse
or
Immediate treatment for recurrent disease (recurrence therapy\(^f\)) (category 2B)

\(^j\)See Principles of Surgery (OV-A).
\(^r\)Patients who progress on 2 consecutive therapy regimens without evidence of clinical benefits have diminished likelihood of benefitting from additional therapy.

Decisions to offer clinical trials, supportive care only, or additional therapy should be made on a highly individual basis.

\(^s\)See Ancillary Palliative Surgical Procedures in Principles of Surgery (OV-A 2 of 2).
\(^t\)See Acceptable Recurrence Therapies (OV-D).
\(^u\)Clinical trials with newer agents should be strongly considered.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
General considerations

- In most instances, a vertical midline abdominal incision should be used in patients with a suspected malignant ovarian/Fallopian tube/primary peritoneal neoplasm in whom a surgical staging procedure, a primary debulking procedure, an interval debulking procedure, or secondary cytoreduction is planned.
- Intraoperative pathologic evaluation with frozen sections may assist in management.
- For select patients, a minimally invasive surgical approach may be employed by an experienced surgeon to achieve the surgical staging and debulking principles subsequently described. In addition, minimally invasive surgical approaches may be useful when evaluating whether maximum cytoreduction can be achieved in patients with newly diagnosed or recurrent ovarian cancer.
- Surgeons should quantify and document the extent of initial and residual disease in operative notes.
- It is recommended that a gynecologic oncologist perform the appropriate surgery.

The following surgical procedures should be considered for patients with newly diagnosed invasive epithelial ovarian cancer apparently confined to an ovary or to the pelvis:

- On entering the abdomen, aspiration of ascites or peritoneal lavage should be performed for peritoneal cytologic examinations.
- All peritoneal surfaces should be visualized, and any peritoneal surface or adhesion suspicious for harboring metastasis should be selectively excised or biopsied. In the absence of any suspicious areas, random peritoneal biopsies should be taken from the pelvis, paracolic gutters, and undersurfaces of the diaphragm (diaphragm scraping for Papanicolaou stain is an acceptable alternative).
- Bilateral salpingo-oophorectomy (BSO) and hysterectomy should be performed with every effort to keep an encapsulated mass intact during removal.
- For selected patients desiring to preserve fertility, unilateral salpingo-oophorectomy (USO) may be considered.
- Omentectomy should be performed.
- Para-aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least the level of the inferior mesenteric artery and preferably to the level of the renal vessels.
- The preferred method of dissecting pelvic lymph nodes is bilateral removal of lymph nodes overlying and anterolateral to the common iliac vessel, overlying and medial to the external iliac, overlying and medial to the hypogastric vessels, and from the obturator fossa at a minimum anterior to the obturator nerve.

The following surgical procedures should be considered as part of the surgical management for patients with newly diagnosed invasive epithelial ovarian cancer involving the pelvis and upper abdomen:

In general, every effort should be made to achieve maximum cytoreduction. Residual disease <1 cm defines optimal cytoreduction; however, maximal effort should be made to remove all gross disease since this offers superior survival outcomes.

- Aspiration of ascites (if present) should be performed for peritoneal cytologic examinations. All involved omentum should be removed.
- Suspicious and/or enlarged nodes should be resected, if possible.
- Those patients with tumor nodules outside the pelvis ≤2 cm (presumed stage IIIB) should have bilateral pelvic and para-aortic lymph node dissection as previously described.
- Procedures that may be considered for optimal surgical cytoreduction (in all stages) include bowel resection and/or appendectomy, stripping of the diaphragm or other peritoneal surfaces, splenectomy, partial cystectomy and/or ureteroneocystotomy, partial hepatectomy, partial gastrectomy, cholecystectomy, and/or distal pancreatectomy.
- Select patients with low-volume residual disease after surgical cytoreduction for invasive epithelial ovarian or peritoneal cancer are potential candidates for IP therapy. In these patients, consideration should be given to placement of IP catheter with initial surgery.

---

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**Special Circumstances**

- **Fertility-sparing surgery**
  - USO preserving the uterus and contralateral ovary (fertility-sparing surgery) can be considered for patients with apparent early-stage disease and/or good risk tumors (early-stage invasive epithelial tumors, low malignant potential (LMP) lesions, malignant germ cell tumors, or malignant sex cord-stromal tumors) who wish to preserve fertility. Comprehensive surgical staging should still be performed to rule out occult higher stage disease but may be omitted in pediatric/adolescent patients with clinically apparent early-stage malignant germ cell tumors based on the pediatric surgical literature.

- **Mucinous tumors**
  - Primary invasive mucinous tumors of the ovary are uncommon. Thus, the upper and lower GI tract should be carefully evaluated to rule out an occult GI primary with ovarian metastases and an appendectomy should be performed in patients with a mucinous ovarian neoplasm.

- **LMP tumors**
  - Although data show upstaging with lymphadenectomy, other data show that lymphadenectomy does not affect overall survival. However, omentectomy and multiple biopsies of peritoneum (the most common sites of peritoneal implants) may upstage patients in approximately 30% of cases and may affect prognosis.

- **Secondary cytoreduction**
  - A secondary cytoreduction procedure can be considered in patients with recurrent ovarian cancer who recur more than 12 months since completion of initial chemotherapy, have an isolated focus (or limited foci) of disease amenable to complete resection, and do not have ascites. Patients are encouraged to participate in ongoing trials evaluating the true benefit of secondary cytoreduction.

**Ancillary Palliative Surgical Procedures**

These procedures may be appropriate in select patients:

- Paracentesis/indwelling peritoneal catheter
- Thoracentesis/pleurodesis/video-assisted thoracoscopy/Indwelling pleural catheter
- Ureteral stents/nephrostomy
- Gastrostomy tube/Intestinal stents/Surgical relief of intestinal obstruction

---


---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
General

• Patients with ovarian, Fallopian tube, or peritoneal cancer should be encouraged to participate in clinical trials during all aspects of their diagnosis and treatment.

• Prior to the initiation of any therapy:
  ▶ Patients of child-bearing potential who desire fertility-sparing procedures should be referred to an appropriate fertility specialist. (See NCCN Guidelines for Adolescent and Young Adult Oncology)
  ▶ Goals of systemic therapy should be discussed.
  ▶ Prior to recommending chemotherapy, requirements for adequate organ function and performance status should be met.
  ▶ Patients should be observed closely and treated for any complications during chemotherapy. Appropriate blood chemistry tests should be monitored. Appropriate dose reductions and modifications of chemotherapy should be performed depending on toxicities experienced and goals of therapy.
  ▶ After completion of chemotherapy, patients should be assessed for response during and following treatment and monitored for any long-term complications.
  ▶ Chemosensitivity/resistance and/or other biomarker assays are being used in some NCCN Member Institutions for decisions related to future chemotherapy in situations where there are multiple equivalent chemotherapy options available. The current level of evidence is not sufficient to supplant standard-of-care chemotherapy. (category 3)

For patients with newly diagnosed ovarian, Fallopian tube, or primary peritoneal cancer:

• If they are eligible for chemotherapy, patients should be informed about the different options that are available— that is, IV chemotherapy, a combination of IP and IV chemotherapy, or a clinical trial—so they can decide which is the most the appropriate option. (See OV-B 3 of 3 for dosing and schedule of these regimens).

• Prior to the administration of the combined IP and IV regimen, patients must be apprised of the increased toxicities with the combined regimen when compared to using IV chemotherapy alone (increased myelosuppression, renal toxicities, abdominal pain, neuropathy, GI toxicities, metabolic toxicities, and hepatic toxicities).

• Patients considered for the IP cisplatin and IP/IV paclitaxel regimen should have normal renal function prior to starting, a medically appropriate performance status based on the future toxicities of the IP/IV regimen, and no prior evidence of medical problems that could significantly worsen during chemotherapy (e.g., pre-existing neuropathy).

• Prior to receiving and after receiving each cycle of IP cisplatin, adequate amounts of IV fluids need to be administered in order to prevent renal toxicity. After each cycle has been completed, patients need to be monitored carefully for myelosuppression, dehydration, electrolyte loss, end-organ toxicities (such as renal and hepatic damage), and all other toxicities. Patients often require IV fluids postchemotherapy in the outpatient setting to prevent or help treat dehydration.

• Refer to the original references (See Discussion) for full toxicity data, doses, schedule, and dose modifications.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
For patients who have recurrent ovarian, Fallopian tube, or primary peritoneal cancer:

- Refer to the original references (See Discussion) for full toxicity data, doses, schedule, and dose modifications.
- Patients should be informed about the following:
  1) Availability of clinical trials, including the risks and benefits of various treatments, which will depend on the number of prior lines of chemotherapy the patient has received, and
  2) The patient’s performance status, end-organ status, and pre-existing toxicities from prior regimens. If appropriate, palliative care should also be discussed as a possible treatment choice. See NCCN Guidelines for Palliative Care.
- Because of prior platinum exposure, myelosuppression occurs more frequently with any myelotoxic agent given in the recurrent setting.
- With repeat use of either carboplatin and/or cisplatin, patients are at an increased risk of developing a hypersensitivity reaction (also called an allergic reaction) that could be life threatening. Thus, patients should be counseled about the risk that a hypersensitivity reaction may occur, educated about the signs and symptoms of hypersensitivity reactions, treated by medical staff who know how to manage hypersensitivity reactions, and treated in a medical setting where appropriate medical equipment is available in case of an allergic reaction. See Management of Drug Reactions (OV-C).
- Before any chemotherapy drug is given in the recurrent setting, the clinician should be familiar with the drug’s metabolism (ie, renal, hepatic) and should make certain that the patient is an appropriate candidate for the drug (eg, that the patient has adequate renal or hepatic function).
- Clinicians should be familiar with toxicity management and appropriate dose reduction.
- The schedule, toxicity, and potential benefits of any treatment should be thoroughly discussed with the patient and caregivers. Patient education should also include a discussion of precautions and measures to reduce the severity and duration of complications.

For elderly patients (>age 65) and/or those with comorbidities

- Elderly patients and those with comorbidities may be intolerant to the combination chemotherapy regimens recommended in these NCCN Guidelines. Single-agent platinum agents may be appropriate in selected patients.
  - Algorithms have been developed for predicting chemotherapy toxicity. See the NCCN Guidelines for Senior Adult Oncology.

Definitions used in the NCCN Guidelines for Ovarian Cancer

- Adjuvant therapy: Drugs, radiation, or other forms of supplemental treatment following cancer surgery intended to decrease the risk of disease recurrence or to primarily treat residual disease, whether gross or microscopic, following surgical cytoreduction.
- Neo-adjuvant therapy: Drugs, radiation, or other forms of treatment given prior to cancer surgery intended to reduce tumor burden in preparation for surgery.
- Recurrence therapy: Drugs, radiation, or other forms of treatment used to treat recurrent cancer, control symptoms, or increase length and/or quality of life at the time of clinical, biochemical, or radiographic evidence of recurrent cancer following the initial treatment.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF CHEMOTHERAPY 
(FOR OVARIAN, FALLOPIAN TUBE, AND PRIMARY PERITONEAL CANCER) 
(3 of 3)

PRIMARY CHEMOTHERAPY/PRIMARY ADJUVANT THERAPY REGIMENS FOR STAGE II-IV

1. Intraperitoneal (IP)/Intravenous (IV) Regimen
   - Paclitaxel 135 mg/m² IV continuous infusion over 3 or 24 h³ Day 1; cisplatin 75-100 mg/m² IP, Day 2 after IV paclitaxel; paclitaxel 60 mg/m² IP Day 8. Repeat every 3 weeks x 6 cycles. (category 1)

2. Intravenous (IV) Regimens
   - Paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin⁴ AUC 5-7.5 IV over 1 hour Day 1. Repeat every 3 weeks x 6 cycles. (category 1)
   - Dose-dense paclitaxel 80 mg/m² IV over 1 hour Days 1, 8, and 15 and carboplatin⁴ AUC 6 IV over 1 hour Day 1. Repeat every 3 weeks x 6 cycles. (category 1)
   - Docetaxel 60-75 mg/m² IV over 1 hour followed by carboplatin⁴ AUC 5-6 IV over 1 hour Day 1. Repeat every 3 weeks x 6 cycles. (category 1)
   - Bevacizumab-containing regimens per ICON-7 and GOG-218:
     - Paclitaxel 175 mg/m² IV over 3 hours, carboplatin⁴ AUC 5-6 IV over 1 hour, and bevacizumab 7.5 mg/kg IV over 30-90 minutes Day 1. Repeat every 3 weeks x 5-6 cycles. Continue bevacizumab for up to 12 additional cycles. (category 3)
     - Paclitaxel 175 mg/m² IV over 3 hours and carboplatin⁴ AUC 6 IV over 1 hour Day 1. Repeat every 3 weeks x 6 cycles. Starting Day 1 of cycle 2, give bevacizumab 15 mg/kg IV over 30-90 minutes every 3 weeks for up to 22 cycles. (category 3)

---

1. See Discussion for references.
2. IV regimens may be considered for neoadjuvant therapy.
3. The published randomized trial regimen used IV continuous infusion paclitaxel over 24 h.
4. Due to changes in creatinine methodology, changes regarding carboplatin dosing can be considered. See FDA carboplatin dosing statement.
**Overview**

- Virtually all drugs used in oncology have the potential to cause adverse drug reactions while being infused, which can be classified as either infusion or allergic reactions.⁴
  - Infusion reactions are often characterized by milder symptoms (eg, hot flushing, rash).
  - Hypersensitivity (allergic) reactions are often characterized by more severe symptoms (eg, shortness of breath, generalized hives/itching, changes in blood pressure).
  - Symptoms can overlap, whether caused by infusion or allergic reactions. In addition, patients can have mild allergic reactions or severe infusion reactions.
- Most adverse drug reactions that occur are mild reactions, but more severe reactions can occur.²,³
  - Anaphylaxis is a rare type of very severe allergic reaction that can occur with the platinum and taxane agents (and others less commonly), can cause cardiovascular collapse, and can be life threatening.⁴-⁶
  - Drug reactions can occur either during the infusion or following completion of the infusion (and can even occur days later).
  - Reactions can occur with either IV or IP administration.
- In gynecologic oncology treatment, drugs that more commonly cause adverse reactions include carboplatin, cisplatin, docetaxel, liposomal doxorubicin, oxaliplatin, and paclitaxel.¹
  - Adverse reactions associated with taxane drugs (ie, docetaxel, paclitaxel) and biotherapeutic agents tend to be infusion related often attributed to cremophor in paclitaxel and tend to occur during the first few cycles of treatment (although they can be seen during any infusion regardless of how many previous cycles were administered).
  - Adverse reactions associated with platinum drugs (ie, carboplatin, cisplatin), a true allergy, tend to occur following re-exposure to the inciting drug or less commonly at the completion of initial chemotherapy (ie, cycle 6 of a planned 6 treatments).³

**MANAGEMENT OF DRUG REACTIONS (1 of 7)**

- Preparation for a possible drug reaction
  - Patients and their families need to be counseled about the possibility of a drug reaction, and about the signs and symptoms of an adverse reaction (either infusion or allergic). Patients should be told to report any signs and symptoms of a drug reaction, especially after they have left the clinic.
  - Clinicians and nursing staff should be prepared for the possibility of a drug reaction every time a patient is infused with a drug.
  - Standing orders should be written for immediate intervention in case a severe drug reaction occurs.
  - The treatment area should have appropriate medical equipment in case of a life-threatening reaction.⁵
  - Epinephrine (intramuscular 0.3 mL of 1 mg/mL solution/Epipen) should be used for any patient experiencing hypotension (systolic BP of <90 mm Hg) with or without other symptoms of an allergic/hypersensitivity reaction during or shortly after any chemotherapy drug treatment. In the setting of acute cardiopulmonary arrest, standard resuscitation (ACLS) procedures should be followed.
- Desensitization refers to a process of rendering the patient less likely to respond to an allergen and can be considered for patients who have had drug reactions.¹,⁷-⁹
  - Although desensitization is more commonly used after allergic drug reactions, it can also be used after infusion reactions.
  - If a mild reaction has previously occurred to a platinum agent, great caution should be undertaken if desensitization is pursued (see Allergic Reactions).
  - If a patient has previously had a very severe life-threatening reaction, the implicated drug should not be used again unless under guidance of an allergist or specialist with desensitization experience.
**Infusion Reactions**

- Symptoms include: hot flushing, rash, fever, chest tightness, mild blood pressure changes, back pain, and chills.
- Symptoms usually can be treated by decreasing the infusion rate and resolve quickly after stopping the infusion. However, patients who have had mild reactions to carboplatin, cisplatin, or oxaliplatin may develop more serious reactions even when the platinum drug is slowly infused; therefore, consider consultation with an allergist.
- More common with paclitaxel (27% of patients); however, mild reactions can occur with liposomal doxorubicin.
- If an infusion reaction has previously occurred to a taxane:
  - For mild infusion reactions (e.g., flushing, rash, chills), patients may be rechallenged with the taxane if:
    1) the patient, physician, and nursing staff are all comfortable with this plan;
    2) the patient has been counseled appropriately; and
    3) emergency equipment is available in the clinic area.
  - Typically the taxane infusion can be re-started at a much slower rate, and the rate can be slowly increased as tolerated as per the treating clinician’s judgment.
  - Note that this slow infusion is different from desensitization.
  - Many institutions have nursing policies that stipulate how to reinfuse the drug if the patient has had a prior infusion reaction.

**Allergic Reactions (i.e., True Drug Allergies)**

- Symptoms include: rash, edema, shortness of breath, syncope or pre-syncope, chest pain, tachycardia, hives/itching, changes in blood pressure, nausea, vomiting, chills, and changes in bowel function. Patients with severe reactions may have the following symptoms: cardiac problems, bronchospasm, blood pressure changes that require treatment, and feeling of impending doom.
- Symptoms continue to persist after stopping infusion and/or after treatment interventions.
- More common with platinum drugs such as carboplatin (16% of patients), cisplatin, and oxaliplatin. Mild reactions can occur with platinum agents.
- Patients who are at higher risk of developing a hypersensitivity (allergic) reaction include those in the following settings:
  - Re-introduction of the drug after a period of no exposure and following multiple cycles of the drug during the first and subsequent exposures
  - Intravenous administration of the drug rather than oral or intraperitoneal administration
  - With allergies to other drugs
  - Those who have previously had a reaction
- If an allergic reaction has previously occurred:
  - Consider consultation with an allergist (or qualified medical or gynecologic oncologist) and skin testing for patients who have experienced a platinum reaction (e.g., carboplatin-hypersensitivity reaction).
  - Patients who have had mild reactions may develop more serious reactions even when the platinum drug is slowly infused. The desensitization treatment of these patients should be managed by a physician with expertise and experience in platinum desensitization.
  - For very severe life-threatening reactions (i.e., anaphylaxis), the implicated drug should not be used again unless under guidance of an allergist or specialist with desensitization experience.
  - For more severe reactions--such as those involving blood pressure changes, dyspnea, tachycardia, widespread urticaria, hypoxia--the treating clinician should consult an allergist prior to rechallenge.
  - If it is appropriate to give the drug again, patients should be desensitized prior to resuming chemotherapy even if the symptoms have resolved. Patients must be desensitized with each infusion if they previously had a drug reaction.

**References on OV-C 3 of 7**
MANAGEMENT OF DRUG REACTIONS (3 of 7)

REFERENCES


See Drug Reaction to Platinum Agents on OV-C 4 of 7
See Drug Reaction to Taxane, Liposomal Doxorubicin, or Biotherapeutic Agents on OV-C 6 of 7
**DRUG REACTION TO PLATINUM AGENTS**

**MANAGEMENT OF DRUG REACTIONS (4 of 7)**

**REACTION**

**FIRST EXPOSURE**
- **Mild reaction**
  - (hot flushing, rash, pruritus)
  - Decrease the infusion rate
  - Symptoms often resolve quickly after stopping infusion
  - Administer antihistamine

**SECOND OR FURTHER EXPOSURE**
- **Severe reaction**
  - (shortness of breath, changes in blood pressure requiring treatment, dyspnea, GI symptoms [nausea, vomiting])
  - Stop infusion
  - Administer antihistamine to treat symptoms
  - Corticosteroid ± IM epinephrine

- **Life-threatening reaction**
  - (ie, anaphylaxis) (acute onset, generalized hives, respiratory compromise, severe hypotension, GI symptoms [nausea, vomiting])

**TREATMENT**

- **First exposure (platinum naive)**
  - Decrease the infusion rate
  - Symptoms often resolve quickly after stopping infusion
  - Administer antihistamine

- **Second or further exposure**
  - Consider allergy consultation
  - Do not rechallenge/readminister drug until evaluated by allergist or specialist with desensitization expertise
  - Potential candidate for desensitization

- **See OV-C 5 of 7**

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**See Drug Reaction to Taxane, Liposomal Doxorubicin, or Biotherapeutic Agents on OV-C 6 of 7**

5Mild reactions can progress to severe reactions by re-exposure. An allergy consultation may provide skin testing and evaluate sensitization and the risk for further, more severe reactions.

6Referral to academic center with expertise in desensitization is preferred.

**NCCN Guidelines Version 3.2014**

**Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer**

**DRUG REACTION TO PLATINUM AGENTS**

**REACTION**

**MANAGEMENT/TREATMENT**

**Mild reaction**

(1) Hot flushing, rash, pruritus

See OV-C 4 of 7

**Severe reaction**

(2) Shortness of breath, changes in blood pressure, dyspnea, GI symptoms (nausea, vomiting)

Stop infusion
- Administer oxygen, nebulized bronchodilators, H2 blockers, corticosteroid; IM epinephrine if needed

**Life-threatening reaction**

(2) Immediate (acute onset, generalized hives, respiratory compromise, severe hypotension, GI symptoms (nausea, vomiting))

Stop infusion
- Administer IM epinephrine, oxygen, nebulized bronchodilators, H2 blockers, corticosteroid
- Saline bolus, if needed

- Potential candidate for desensitization with each infusion

- Do not rechallenge/readminister the drug until evaluated by an allergist or specialist with desensitization expertise

- Do not rechallenge/readminister the drug until evaluated by an allergist or specialist with desensitization expertise

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

1. Most mild reactions are infusion reactions and more commonly are caused by taxanes (ie, docetaxel, paclitaxel), but can also occur with platinum agents (ie, carboplatin, cisplatin).
2. Most severe reactions are allergic reactions and more commonly are caused by platinum agents.
3. Antihistamine (eg, diphenhydramine or hydroxyzine); H2 blockers (eg, cimetidine, famotidine); corticosteroids (eg, methylprednisolone, hydrocortisone, dexamethasone).
4. In the setting of acute cardiopulmonary arrest, standard resuscitation (ACLS) procedures should be followed.

6. Referral to academic center with expertise in desensitization is preferred.


8. For both taxanes and platinum analogues, it is preferred that anyone with a life-threatening reaction be evaluated and referred to an academic center if the drug is still considered first line.
**MANAGEMENT OF DRUG REACTIONS (6 of 7)**

**MANAGEMENT/TREATMENT**

**Mild reaction**
- Stop infusion
- Symptoms often resolve quickly after stopping infusion
- Administer antihistamine to treat symptoms

**Severe reaction**
- If staff agree and vital signs remain stable, rechallenge with drug at slower infusion rate
- Administer premedication with antihistamine, corticosteroids, H2 blockers

**Life-threatening reaction**
- If repeat mild reaction, then do not rechallenge/readminister
- Potential candidate for desensitization with each infusion

---

1 Most mild reactions are infusion reactions and more commonly are caused by taxanes (ie, docetaxel, paclitaxel), but can also occur with platinum agents (ie, carboplatin, cisplatin).

2 Most severe reactions are allergic reactions and more commonly are caused by platinum agents.

3 Antihistamine (eg, diphenhydramine or hydroxyzine); H2 blockers (eg, cimetidine, famotidine); corticosteroids (eg, methylprednisolone, hydrocortisone, dexamethasone).


9 Consider switching to docetaxel; however, there are no data to support switching taxanes. Cross reactions have occurred and have been life-threatening. Some reactions to paclitaxel may occur because of the diluent.
### DRUG REACTION TO TAXANE, LIPOSOMAL DOXORUBICIN, OR BIOOTHERAPEUTIC AGENTS

<table>
<thead>
<tr>
<th>REACTION</th>
<th>MANAGEMENT/TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild reaction¹ (hot flushing, rash, pruritus, pain in chest/abdomen/pelvis/back)</td>
<td>See OV-C 6 of 7</td>
</tr>
<tr>
<td>Severe reaction² (shortness of breath, changes in blood pressure requiring treatment, dyspnea, GI symptoms [nausea, vomiting], pain in chest/abdomen/pelvis/back, feeling of impending doom/anxiety/something wrong)</td>
<td>• Stop infusion&lt;br&gt;• Administer oxygen, nebulized bronchodilator, antihistamine, H2 blockers, corticosteroid; IM epinephrine if needed⁴</td>
</tr>
<tr>
<td>Life-threatening reaction² (ie, anaphylaxis) (acute onset, generalized hives, respiratory compromise, severe hypotension, GI symptoms [nausea, vomiting], pain in chest/abdomen/pelvis/back, feeling of impending doom/anxiety/something wrong)</td>
<td>• Do not rechallenge/readminister drug until evaluated by allergist or specialist with desensitization expertise&lt;br&gt;• Potential candidate for desensitization⁶,⁷ with each infusion</td>
</tr>
</tbody>
</table>

¹Most mild reactions are infusion reactions and more commonly are caused by taxanes (ie, docetaxel, paclitaxel), but can also occur with platinum agents (ie, carboplatin, cisplatin).

²Most severe reactions are allergic reactions and more commonly are caused by platinum agents.

³Antihistamine (eg, diphenhydramine or hydroxyzine); H2 blockers (eg, cimetidine, famotidine); corticosteroids (eg, methylprednisolone, hydrocortisone, dexamethasone).

⁴In the setting of acute cardiopulmonary arrest, standard resuscitation (ACLS) procedures should be followed.

⁵Referral to academic center with expertise in desensitization is preferred.


⁷For both taxanes and platinum analogues, it is preferred that anyone with a life-threatening reaction be evaluated and referred to an academic center if the drug is still considered first line.

---

**See Drug Reaction to Platinum Agents on OV-C 4 of 7**

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### ACCEPTABLE RECURRENCE THERAPIES (1 OF 2)\(^a\)

<table>
<thead>
<tr>
<th>Preferred Single Agents or Combinations</th>
<th>Cytotoxic Therapy (In alphabetical order)</th>
<th>Hormonal Therapy</th>
<th>Targeted Therapy</th>
<th>Radiation Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Platinum-Sensitive Disease(^b,c)</strong></td>
<td>Carboplatin(^1)</td>
<td></td>
<td></td>
<td>Bevacizumab(^d,e,17,18)</td>
</tr>
<tr>
<td></td>
<td>Carboplatin/docetaxel(^2,3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carboplatin/gemcitabine(^1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carboplatin/gemcitabine/bevacizumab(^d,e) (category 2B)(^4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carboplatin/liposomal doxorubicin(^5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carboplatin/paclitaxel (category 1)(^6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carboplatin/paclitaxel (weekly)(^7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cisplatin(^8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cisplatin/gemcitabine(^8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Platinum-Resistant Disease</strong></td>
<td>Docetaxel(^9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Etoposide, oral(^10)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gemcitabine(^11,12)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Liposomal doxorubicin(^11,12)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Liposomal doxorubicin/bevacizumab(^d,e,13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paclitaxel (weekly)(^14)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paclitaxel (weekly)/bevacizumab(^d,e,13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topotecan(^15,16)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topotecan/bevacizumab(^d,e,13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other Potentially Active Agents</strong></td>
<td>Single Agents(^19)</td>
<td></td>
<td></td>
<td>Palliative localized radiation therapy</td>
</tr>
<tr>
<td></td>
<td>Altretamine</td>
<td>Melphalan</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Capecitabine</td>
<td>Oxaliplatin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cyclophosphamide</td>
<td>Paclitaxel</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Doxorubicin</td>
<td>Paclitaxel, albumin bound (nab-paclitaxel)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ifosfamide</td>
<td>Pemetrexed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Irinotecan</td>
<td>Vinorelbine</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^a\)Patients who progress on two consecutive therapy regimens without evidence of clinical benefits have diminished likelihood of benefitting from additional therapy. (Griffiths RW, et al. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and Fallopian tube. Int J Gyn Ca 2011;21:58-65.) Decisions to offer clinical trials, supportive care, or additional therapy should be made on a highly individual basis.

\(^b\)In general, the Panel would recommend combination regimens based on randomized trial data, especially in first relapses.

\(^c\)Platinum-based combination therapy should be considered for platinum-sensitive recurrences.

\(^d\)In patients who have not previously received bevacizumab.

\(^e\)Contraindicated for patients at increased risk of gastrointestinal perforation.

See References (OV-D 2 of 2)
REFERENCES


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Malignant Germ Cell Tumors

**Initial surgery**
- **Fertility desired**
  - Fertility-sparing surgery and comprehensive staging
    - (See OV-A)
  - Complete staging surgery
    - (See OV-A)
- **Fertility not desired**
  - Consider observation (category 2B)
    - (See LCOH-B)

**Malignant germ cell tumors**

**Incompletely surgically staged**
- Dysgerminoma or grade 1 immature teratoma
  - Positive imaging and positive tumor markers
  - Fertility desired, then fertility-sparing surgery and comprehensive staging; fertility not desired, then completion staging surgery
    - (See OV-A)
  - Negative imaging and positive tumor markers
  - Consider observation (category 2B)
    - (See LCOH-B)

**Embryonal, endodermal sinus tumor (yolk sac tumor), grade 2-3 immature teratoma, or mixed histology**
- Positive imaging and positive tumor markers
  - Fertility desired, then fertility-sparing surgery and comprehensive staging; fertility not desired, then completion staging surgery with possible tumor reductive surgery
    - (See OV-A)
  - Negative imaging and positive tumor markers
  - Chemotherapy
    - (See LCOH-3)

**Prior surgery**
- **Fertility desired**, then fertility-sparing surgery and comprehensive staging; fertility not desired, then completion staging surgery
  - or
  - Chemotherapy
    - (See LCOH-3)

**Completely staged**
(See OV-A)

**Note:** All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Surgical principles for pediatric/young adult patients may differ from those for adult patients. See Principles of Surgery (OV-A).

Standard recommendation includes a patient evaluation by a gynecologic oncologist.
### NCCN Guidelines Version 3.2014

#### Malignant Germ Cell Tumors

**Clinical Presentation**

<table>
<thead>
<tr>
<th>Stage I Dysgerminoma</th>
<th>Stage I, grade I Immature teratoma</th>
<th>Any stage Embryonal tumor</th>
<th>Any stage Endodermal sinus tumor (yolk sac tumor)</th>
<th>Stage II-IV Dysgerminoma</th>
<th>Stage I, grade 2 or 3 or Stage II-IV Immature teratoma</th>
</tr>
</thead>
</table>

**Treatment**

- **Observe**
  - See Surveillance for Germ Cell and Sex-Cord Stromal Tumors (LCOH-B)

**Monitoring/Follow-Up**

- **Complete clinical response**
  - Residual tumor on radiographic imaging; markers normal

**Recurrent/Persistent Disease**

<table>
<thead>
<tr>
<th>Abnormal markers, definitive recurrent disease</th>
<th>Complete clinical response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Necrotic tissue</td>
<td>Incomplete clinical response</td>
</tr>
<tr>
<td>Benign teratoma</td>
<td>Consider additional platinum-based chemotherapy (category 2B) or Observe (category 2B) (See LCOH-B)</td>
</tr>
<tr>
<td>CT or other imaging as clinically indicated</td>
<td>Consider additional platinum-based chemotherapy (category 2B) or Observe (category 2B) (See LCOH-B)</td>
</tr>
<tr>
<td>Residual tumor</td>
<td>TIP (paclitaxel/ifosfamide/cisplatin) or High-dose chemotherapy (strongly recommend referral to tertiary care center for potentially curative regimen)</td>
</tr>
</tbody>
</table>

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Malignant sex cord-stromal tumors

- **Stage IA/IC:**
  - Desires fertility

- **All others**

TREATMENT RECURRENT DISEASE RECURRENT THERAPY

**Stage I Low risk**
- Observe^k (See LCOH-B)

**Stage I High risk**
- Low risk (eg, ruptured stage IC or poorly differentiated stage I)
- Intermediate risk (eg, heterologous elements)
  - Observe^k (category 2B) (See LCOH-B)
  - Consider platinum-based chemotherapy^l (category 2B)

**Stage II-IV**
- Platinum-based chemotherapy^l (category 2B) or RT for limited disease (category 2B)
- Clinical relapse
- Clinical trial or Consider secondary cytoreductive surgery or Recurrence therapy^h

---

^a See Sex Cord-Stromal Tumors - WHO Histologic Classification (LCOH-A).
^b See Acceptable Recurrence Therapies (LCOH-C).
^c Lymphadenectomy may be omitted.
^d See Principles of Surgery (OV-A).
^e Inhibin levels can be followed if initially elevated for granulosa cell tumors (category 2B).
^f Malignant germ cell regimens (See LCOH-3) or paclitaxel/carboplatin regimens are preferred.

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### Carcinosarcoma (Malignant Mixed Müllerian Tumors) of the Ovary

<table>
<thead>
<tr>
<th>CLINICAL PRESENTATION</th>
<th>TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete surgical staging(^1)</td>
<td>Stage I-IV or Recurrence</td>
</tr>
</tbody>
</table>

\(^1\)See Principles of Surgery (OV-A).

---

\*Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.*
### CLINICAL PRESENTATION

#### Diagnosis of LMP tumor with institutional pathology review

- **Previous surgical staging was comprehensive**
  - **No invasive implants** → **Observe**
  - **Invasive implants** → **Consider treatment as epithelial ovarian cancer** (category 2B) (See OV-2)

- **Incomplete surgical staging** → **See LCOH-7**

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

### PRIMARY TREATMENT

- **See Monitoring/Follow-up (LCOH-8)**
**CLINICAL PRESENTATION**

**No invasive implants or Unknown**
- Fertility desired
  - Fertility-sparing surgery and comprehensive surgical staging, (category 2B for staging) if not previously done
- Observation

**No residual disease remaining after first procedure**
- If no desire for fertility
  - Observation
- Invasive implants at previous surgery
  - Observation

**Residual disease remaining after first procedure**
- Fertility-sparing surgery and comprehensive surgical staging, (category 2B for staging) if not previously done
- Observation (category 2B)
- Consider treatment as epithelial ovarian cancer (category 2B) (See OV-2)

**No invasive implants or Unknown**
- Observation
- Completion surgery

**Invasive implants at previous surgery**
- Observation
- Consider treatment as epithelial ovarian cancer (category 2B) (See OV-2)

---

1. See Principles of Surgery (OV-A).
2. Standard recommendation includes a patient evaluation by a gynecologic oncologist.
3. Chemotherapy (IV or IP) has not been shown to be beneficial in ovarian low malignant potential tumors (borderline epithelial ovarian tumors).
4. Observation is a reasonable option regardless of whether fertility is desired.
5. For pathologically proven LMP, lymph node evaluation may be considered on a case-by-case basis.

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**MONITORING/FOLLOW-UP**

- Visits every 3-6 mo for up to 5 y, then annually
- Physical exam including pelvic exam
- CA-125\(^q\) or other tumor markers every visit if initially elevated
- After completion of childbearing in patients who underwent USO, consider completion surgery (category 2B)
- CBC, chemistry profile as indicated
- Ultrasound as indicated for patients with fertility-sparing surgery

**RECURRENT DISEASE**

- Clinical relapse
- Surgical evaluation + debulking if appropriate

**RECURRENT THERAPY**

- Noninvasive disease
  - Observe
- Invasive disease
  - Treatment as epithelial ovarian cancer\(^n\) (category 2B)
  - See OV-3

\(n\)Chemotherapy (IV or IP) has not been shown to be beneficial in ovarian low malignant potential tumors (borderline epithelial ovarian tumors).

\(q\)There are data regarding the utility of CA-125 for monitoring of ovarian cancer after completion of primary therapy. See The Society of Gynecologic Oncology (SGO) position statement and Discussion.

---

**MONITORING/FOLLOW-UP**

- Visits every 3-6 mo for up to 5 y, then annually
- Physical exam including pelvic exam
- CA-125\(^q\) or other tumor markers every visit if initially elevated
- After completion of childbearing in patients who underwent USO, consider completion surgery (category 2B)
- CBC, chemistry profile as indicated
- Ultrasound as indicated for patients with fertility-sparing surgery

**RECURRENT DISEASE**

- Clinical relapse
- Surgical evaluation + debulking if appropriate

**RECURRENT THERAPY**

- Noninvasive disease
  - Observe
- Invasive disease
  - Treatment as epithelial ovarian cancer\(^n\) (category 2B)
  - See OV-3

\(n\)Chemotherapy (IV or IP) has not been shown to be beneficial in ovarian low malignant potential tumors (borderline epithelial ovarian tumors).

\(q\)There are data regarding the utility of CA-125 for monitoring of ovarian cancer after completion of primary therapy. See The Society of Gynecologic Oncology (SGO) position statement and Discussion.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
## SEX CORD-STROMAL TUMORS - WHO HISTOLOGIC CLASSIFICATION

- Sex cord-stromal tumors are a heterogeneous group of very rare tumors from benign to aggressive, and each histology has a range of often well differentiated to undifferentiated. Therefore, it should be determined whether a patient has a malignant or benign sex cord-stromal tumor.
- Treatment decisions and the decision whether to preserve fertility must be individualized based on the patient's specific tumor features.

<table>
<thead>
<tr>
<th>WHO Histologic Classification</th>
<th>Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Granulosa cell tumors</strong></td>
<td></td>
</tr>
<tr>
<td>Adult</td>
<td>Malignant</td>
</tr>
<tr>
<td>Juvenile</td>
<td>Malignant</td>
</tr>
<tr>
<td><strong>Thecoma</strong></td>
<td></td>
</tr>
<tr>
<td>Thecomas, typical</td>
<td>Benign</td>
</tr>
<tr>
<td>Thecomas, luteinized</td>
<td>Malignant potential</td>
</tr>
<tr>
<td>Thecoma with increased mitotic figures</td>
<td>Malignant potential</td>
</tr>
<tr>
<td><strong>Fibroma</strong></td>
<td></td>
</tr>
<tr>
<td>Cellular fibroma</td>
<td>Malignant potential</td>
</tr>
<tr>
<td>Cellular fibroma with increased mitotic figures</td>
<td>Malignant potential</td>
</tr>
<tr>
<td>Fibrosarcoma</td>
<td>Malignant</td>
</tr>
<tr>
<td>Stromal tumor with minor sex cord elements</td>
<td>Benign</td>
</tr>
<tr>
<td>Sclerosing stromal tumor</td>
<td>Benign</td>
</tr>
<tr>
<td>Signet ring stromal tumors</td>
<td>Benign</td>
</tr>
<tr>
<td>Unclassified</td>
<td>Malignant potential</td>
</tr>
<tr>
<td><strong>Sertoli-Leydig cell tumors</strong></td>
<td></td>
</tr>
<tr>
<td>Well differentiated</td>
<td>Malignant potential</td>
</tr>
<tr>
<td>Intermediate differentiation</td>
<td>Malignant</td>
</tr>
<tr>
<td>Poorly differentiated</td>
<td>Malignant</td>
</tr>
<tr>
<td>Sertoli-Leydig tumors with heterologous elements</td>
<td>Malignant</td>
</tr>
<tr>
<td>Sertoli cell tumors</td>
<td>Malignant potential</td>
</tr>
<tr>
<td>Leydig cell tumors</td>
<td>Malignant</td>
</tr>
<tr>
<td>Stromal-Leydig cell tumors</td>
<td>Benign</td>
</tr>
<tr>
<td>Sex cord tumors with annular tubules (SCTAT)</td>
<td>Malignant</td>
</tr>
<tr>
<td>Microscopic SCTAT associated with Peutz-Jeghers syndrome</td>
<td>Benign</td>
</tr>
<tr>
<td>Gynandroblastoma</td>
<td>Malignant/Malignant potential</td>
</tr>
<tr>
<td>Unclassified sex cord stromal tumors</td>
<td>Malignant potential</td>
</tr>
<tr>
<td>Steroid cell tumors</td>
<td>Malignant</td>
</tr>
</tbody>
</table>

1Adapted from Tavassoel FA, Devilee P (Eds): WHO Classification of Tumours, Pathology and Genetics: Tumours of the Breast and Female Genital Organs. IARC, Lyon, 2003.
### SURVEILLANCE FOR GERM CELL AND SEX CORD-STROMAL TUMORS

<table>
<thead>
<tr>
<th></th>
<th>&lt;1</th>
<th>1-2</th>
<th>2-3</th>
<th>3-5</th>
<th>&gt;5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physical Exam</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germ cell tumors</td>
<td>Every 2-4 mo</td>
<td>Every 2-4 mo</td>
<td>Yearly</td>
<td>Yearly</td>
<td>Yearly</td>
</tr>
<tr>
<td>Sex cord-stromal tumors</td>
<td>Every 2-4 mo</td>
<td>Every 2-4 mo</td>
<td>Every 6 mo</td>
<td>Every 6 mo</td>
<td>Every 6 mo</td>
</tr>
<tr>
<td><strong>Serum tumor markers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germ cell tumors</td>
<td>Every 2-4 mo</td>
<td>Every 2-4 mo</td>
<td>Not indicated</td>
<td>Not indicated</td>
<td>Not indicated</td>
</tr>
<tr>
<td>Sex cord-stromal tumors</td>
<td>Every 2-4 mo</td>
<td>Every 2-4 mo</td>
<td>Every 6 mo</td>
<td>Every 6 mo</td>
<td>Every 6 mo</td>
</tr>
<tr>
<td><strong>Radiographic imaging</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germ cell tumors</td>
<td>Not indicated unless markers normal at initial presentation</td>
<td>Not indicated unless markers normal at initial presentation</td>
<td>Not indicated</td>
<td>Not indicated</td>
<td>Not indicated</td>
</tr>
<tr>
<td>Sex cord-stromal tumors</td>
<td>Insufficient data to support routine use</td>
<td>Insufficient data to support routine use</td>
<td>Insufficient data to support routine use</td>
<td>Insufficient data to support routine use</td>
<td>Insufficient data to support routine use</td>
</tr>
<tr>
<td><strong>Recurrence suspected</strong></td>
<td>CT scan and tumor markers **</td>
<td>CT scan and tumor markers **</td>
<td>CT scan and tumor markers **</td>
<td>CT scan and tumor markers **</td>
<td>CT scan and tumor markers **</td>
</tr>
</tbody>
</table>


**Chest x-ray, CT, MRI

**See LCOH-1 for markers.

---

1. All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### Acceptable Recurrence Therapies

#### Malignant Germ Cell Tumors

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-dose chemotherapy</td>
<td>1, 2</td>
</tr>
<tr>
<td>Cisplatin/etoposide</td>
<td></td>
</tr>
<tr>
<td>Docetaxel</td>
<td></td>
</tr>
<tr>
<td>Docetaxel/carboplatin</td>
<td></td>
</tr>
<tr>
<td>Paclitaxel</td>
<td></td>
</tr>
<tr>
<td>Paclitaxel/ifosfamide</td>
<td></td>
</tr>
<tr>
<td>Paclitaxel/carboplatin</td>
<td></td>
</tr>
<tr>
<td>Paclitaxel/gemcitabine</td>
<td></td>
</tr>
<tr>
<td>VIP (etoposide, ifosfamide, cisplatin)</td>
<td></td>
</tr>
<tr>
<td>VelP (vinblastine, ifosfamide, cisplatin)</td>
<td></td>
</tr>
<tr>
<td>VAC (vincristine, dactinomycin, cyclophosphamide)</td>
<td></td>
</tr>
<tr>
<td>TIP (paclitaxel, ifosfamide, cisplatin)</td>
<td></td>
</tr>
<tr>
<td>Radiation therapy</td>
<td></td>
</tr>
<tr>
<td>Supportive care only</td>
<td></td>
</tr>
</tbody>
</table>

#### Malignant Sex Cord-Stromal Tumors

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aromatase inhibitors (anastrozole, letrozole)</td>
<td></td>
</tr>
<tr>
<td>Bevacizumab may be considered for granulosa cell tumors</td>
<td></td>
</tr>
<tr>
<td>Leuprolide may be used as hormonal therapy for granulosa cell tumors</td>
<td></td>
</tr>
<tr>
<td>Docetaxel</td>
<td></td>
</tr>
<tr>
<td>Paclitaxel</td>
<td></td>
</tr>
<tr>
<td>Paclitaxel/ifosfamide</td>
<td></td>
</tr>
<tr>
<td>Paclitaxel/carboplatin</td>
<td></td>
</tr>
<tr>
<td>Tamoxifen</td>
<td></td>
</tr>
<tr>
<td>VAC</td>
<td></td>
</tr>
<tr>
<td>Radiation therapy</td>
<td></td>
</tr>
<tr>
<td>Supportive care only</td>
<td></td>
</tr>
</tbody>
</table>

1. Patients with potentially curable recurrent germ cell disease should be referred to a tertiary care institution for potentially curative therapy.
2. High-dose chemotherapy regimens vary among institutions.
### Staging


An update to the AJCC staging manual (8th ed.) is currently in progress.

#### Table 1

**American Joint Committee on Cancer (AJCC)**

**TNM and FIGO Staging System for Ovarian and Primary Peritoneal Cancer (7th ed., 2010)**

<table>
<thead>
<tr>
<th>Primary Tumor (T)</th>
<th>TNM</th>
<th>FIGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>Primary tumor cannot be assessed</td>
<td></td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumor</td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>Tumor limited to ovaries (one or both)</td>
<td></td>
</tr>
<tr>
<td>T1a</td>
<td>Tumor limited to one ovary; capsule intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings</td>
<td></td>
</tr>
<tr>
<td>T1b</td>
<td>Tumor limited to both ovaries; capsules intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings</td>
<td></td>
</tr>
<tr>
<td>T1c</td>
<td>Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings</td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>Tumor involves one or both ovaries with pelvic extension</td>
<td></td>
</tr>
<tr>
<td>T2a</td>
<td>Extension and/or implants on uterus and/or tube(s). No malignant cells in ascites or peritoneal washings</td>
<td></td>
</tr>
<tr>
<td>T2b</td>
<td>Extension to and/or implants on other pelvic tissues. No malignant cells in ascites or peritoneal washings</td>
<td></td>
</tr>
<tr>
<td>T2c</td>
<td>Pelvic extension and/or implants (T2a or T2b) with malignant cells in ascites or peritoneal washings</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Distant Metastasis (M)</th>
<th>TNM</th>
<th>FIGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
<td></td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis (excludes peritoneal metastasis)</td>
<td></td>
</tr>
</tbody>
</table>

Note: Liver capsule metastasis is T3/stage III; liver parenchymal metastasis, M1/stage IV. Pleural effusion must have positive cytology for M1/stage IV.

### Regional Lymph Nodes (N)

<table>
<thead>
<tr>
<th>Regional Lymph Nodes (N)</th>
<th>TNM</th>
<th>FIGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>NX</td>
<td>Regional lymph nodes cannot be assessed</td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>No regional lymph node metastasis</td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>Regional lymph node metastasis</td>
<td></td>
</tr>
</tbody>
</table>

**Continued**
## Table 1 (Continued)

**American Joint Committee on Cancer (AJCC)**

**TNM and FIGO Staging System for Ovarian and Primary Peritoneal Cancer (7th ed., 2010)**

<table>
<thead>
<tr>
<th>Stage Grouping</th>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Stage 1</strong></td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td><strong>Stage IA</strong></td>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td><strong>Stage IB</strong></td>
<td>T1b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td><strong>Stage IC</strong></td>
<td>T1c</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td><strong>Stage II</strong></td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td><strong>Stage IIA</strong></td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td><strong>Stage IIB</strong></td>
<td>T2b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td><strong>Stage IIC</strong></td>
<td>T2c</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td><strong>Stage III</strong></td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td><strong>Stage IIIA</strong></td>
<td>T3a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td><strong>Stage IIIB</strong></td>
<td>T3b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td><strong>Stage IIIC</strong></td>
<td>T3c</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td><strong>Stage IV</strong></td>
<td>Any T</td>
<td>Any N</td>
<td>M0</td>
</tr>
</tbody>
</table>

Note: For histologic grade and histopathologic type, see AJCC Staging Manual.

The staging system for ovarian and primary peritoneal cancer is also used for malignant germ cell tumors, malignant sex cord-stromal tumors, and carcinosarcoma (malignant mixed Müllerian tumors).


An update to the AJCC staging manual (8th ed.) is currently in progress.
Table 2
American Joint Committee on Cancer (AJCC)
TNM and FIGO Staging System for Fallopian Tube Cancer (7th ed., 2010)

<table>
<thead>
<tr>
<th>Primary Tumor (T)</th>
<th>TNM</th>
<th>FIGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>Primary tumor cannot be assessed</td>
<td>TX</td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumor</td>
<td>T0</td>
</tr>
<tr>
<td>Tis*</td>
<td>Carcinoma in situ (limited to tubal mucosa)</td>
<td>Tis*</td>
</tr>
<tr>
<td>T1</td>
<td>Tumor limited to the Fallopian tube(s)</td>
<td>T1</td>
</tr>
<tr>
<td>T1a</td>
<td>Tumor limited to one tube, without penetrating the serosal surface; no ascites</td>
<td>T1a</td>
</tr>
<tr>
<td>T1b</td>
<td>Tumor limited to both tubes, without penetrating the serosal surface; no ascites</td>
<td>T1b</td>
</tr>
<tr>
<td>T1c</td>
<td>Tumor limited to one or both tubes with extension onto or through the tubal serosa, or with malignant cells in ascites or peritoneal washings</td>
<td>T1c</td>
</tr>
<tr>
<td>T2</td>
<td>Tumor involves one or both Fallopian tubes with pelvic extension</td>
<td>T2</td>
</tr>
<tr>
<td>T2a</td>
<td>Extension and/or metastasis to the uterus and/or ovaries</td>
<td>T2a</td>
</tr>
<tr>
<td>T2b</td>
<td>Extension to other pelvic structures</td>
<td>T2b</td>
</tr>
<tr>
<td>T2c</td>
<td>Pelvic extension with malignant cells in ascites or peritoneal washings</td>
<td>T2c</td>
</tr>
<tr>
<td>T2d</td>
<td>Peritoneal washings and no ascites</td>
<td>T2d</td>
</tr>
<tr>
<td>T3</td>
<td>Tumor involves one or both Fallopian tubes, with peritoneal implants outside the pelvis</td>
<td>T3</td>
</tr>
<tr>
<td>T3a</td>
<td>Microscopic peritoneal metastasis outside the pelvis</td>
<td>T3a</td>
</tr>
<tr>
<td>T3b</td>
<td>Macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension</td>
<td>T3b</td>
</tr>
<tr>
<td>T3c</td>
<td>Peritoneal metastasis outside the pelvis and more than 2 cm in diameter</td>
<td>T3c</td>
</tr>
</tbody>
</table>

Regional Lymph Nodes (N)

| N0               | No regional lymph node metastasis | N0 | N0 |
| N1               | Regional lymph node metastasis | N1 | N1 |
| N2               | Peritoneal washings | N2 | N2 |
| N3               | Abdominal washings | N3 | N3 |
| N4               | Ascites or pleural effusion | N4 | N4 |

Distant Metastasis (M)

| M0               | No distant metastasis | M0 | M0 |
| M1               | Distant metastasis (excludes metastasis within the peritoneal cavity) | M1 | M1 |
| M2               | Multiple sites | M2 | M2 |
| M3               | Peritoneal cavity | M3 | M3 |
| M4               | Peritoneal washings | M4 | M4 |

*Note: FIGO no longer includes stage 0 (Tis)

Note: Liver capsule metastasis is T3/stage III; liver parenchymal metastasis, M1/stage IV. Pleural effusion must have positive cytology for M1/stage IV.


An update to the AJCC staging manual (8th ed.) is currently in progress.

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.cancerstaging.net](http://www.cancerstaging.net).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.
Staging


An update to the AJCC staging manual (8th ed.) is currently in progress.

Table 2 (Continued)

American Joint Committee on Cancer (AJCC)
TNM and FIGO Staging System for Fallopian Tube Cancer (7th ed., 2010)

Stage Grouping

<table>
<thead>
<tr>
<th>Stage</th>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0*</td>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage 1</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IA</td>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IB</td>
<td>T1b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IC</td>
<td>T1c</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage II</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIA</td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIB</td>
<td>T2b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIC</td>
<td>T2c</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage III</td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIA</td>
<td>T3a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIB</td>
<td>T3b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIC</td>
<td>T3c</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IV</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

*Note: FIGO no longer includes stage 0 (Tis)

Note: For histologic grade and histopathologic type, see AJCC Staging Manual.

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.cancerstaging.net](http://www.cancerstaging.net).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.
Discussion

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview ............................................................... MS-3
Screening ............................................................. MS-4
Staging ............................................................... MS-5
Caveat ................................................................ MS-5
Epithelial Ovarian Cancer ........................................ MS-5
Recommended Workup ............................................. MS-5
Undiagnosed Pelvic Mass .......................................... MS-5
Prior Diagnosis of Malignancy ................................... MS-6

Primary Treatment .................................................. MS-7
Cytoreductive Surgery ............................................... MS-7
Neoadjuvant Chemotherapy ....................................... MS-8
Incompletely Staged Patients ..................................... MS-9
Chemotherapy ....................................................... MS-9
Anti-Angiogenesis Agents ......................................... MS-11
Number of Chemotherapy Cycles and Agents ............. MS-12
Drug Reactions ...................................................... MS-12
Radiation Therapy .................................................. MS-13

Recommendations After Primary Treatment .................. MS-13
Follow-up Recommendations ..................................... MS-13
Management of an Increasing CA-125 Level .................. MS-14
Recurrent Disease ................................................ MS-14
Acceptable Recurrence Modalities ................................ MS-15

Less Common Ovarian Histopathologies ....................... MS-17
Overview ............................................................. MS-17
Recommended Workup ............................................. MS-17
Malignant Germ Cell Tumors ..................................... MS-18
Treatment ............................................................. MS-18
Residual or Recurrent Disease ................................... MS-19
NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
Overview

Ovarian neoplasms consist of several histopathologic entities; treatment depends on the specific tumor type. Epithelial ovarian cancer comprises the majority of malignant ovarian neoplasms (about 90%); however, other less common pathologic subtypes may occur. These NCCN Guidelines discuss epithelial ovarian cancer and less common histopathologies, including ovarian low malignant potential [LMP] tumor, malignant germ cell neoplasms, carcinosarcomas (malignant mixed Müllerian tumors [MMMTs] of the ovary), and malignant sex cord-stromal tumors. The NCCN Guidelines also discuss fallopian tube cancer and primary peritoneal cancer, which are less common neoplasms that are managed in a similar manner to epithelial ovarian cancer. However, the less common histologies of ovarian cancer are managed differently. These NCCN Guidelines also include sections on Principles of Chemotherapy (including Acceptable Recurrence Therapies), Principles of Surgery, and Management of Drug Reactions. The Summary of the Guidelines Updates section in the algorithm briefly describes the new changes for 2014; the Principles of Surgery were extensively revised (see the NCCN Guidelines for Ovarian Cancer).

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country’s fifth most common cause of cancer mortality in women. In 2014, it is estimated that 21,980 new diagnoses and 14,270 deaths from this neoplasm will occur in the United States; less than 40% of women with ovarian cancer are cured. The incidence of ovarian cancer increases with age and is most prevalent in the sixth and seventh decades of life. The median age at the time of diagnosis is 63 years, and more than 70% of patients present with advanced disease.

Epidemiologic studies have identified risk factors in the etiology of ovarian cancer. A 30% to 60% decreased risk for cancer is associated with younger age at pregnancy and first birth (≤25 years), the use of oral contraceptives, and/or breastfeeding. Conversely, nulliparity or older age (>35 years) at pregnancy and first birth confers an increased risk for ovarian cancer. Recent data suggest that hormone therapy and pelvic inflammatory disease may increase the risk for ovarian cancer. The risk for ovarian LMP tumors (also known as borderline epithelial ovarian tumors) may be increased after ovarian stimulation for in vitro fertilization. Obesity does not appear to be associated with the most aggressive types of ovarian cancer.

Family history (primarily patients having 2 or more first-degree relatives with ovarian cancer)—including linkage with BRCA1 and BRCA2 genotypes or families affected by Lynch syndrome (hereditary nonpolyposis colorectal cancer [HNPCC] syndrome)—is associated with early-onset disease. However, these patients account for only 5% of all women who have ovarian cancer. In high-risk women (with either BRCA1 or BRCA2 mutations), prophylactic salpingo-oophorectomy is associated with a reduced risk for ovarian and fallopian tube cancers (see Risk Reduction Surgery in the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian). However, there is a residual risk for primary peritoneal cancer in these high-risk women after prophylactic salpingo-oophorectomy. Occult ovarian cancer is sometimes found after prophylactic salpingo-oophorectomy emphasizing the need for careful pathologic review. The risks of surgery include injury to the bowel, bladder, ureter, and vessels. Recently, it has been suggested that the fallopian tube may be the origin of some ovarian and primary peritoneal cancers. Environmental factors have been investigated, but so far...
Screening

Because of the location of the ovaries and the biology of most epithelial cancers, it has been difficult to diagnose ovarian cancer at an earlier, more curable stage. However, evaluations of newly diagnosed ovarian cancer patients have resulted in consensus guidelines for ovarian cancer symptoms, which may enable earlier identification of patients who may be at an increased risk of having developed early-stage ovarian cancer.46,47 Symptoms suggestive of ovarian cancer include: bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary symptoms (urgency or frequency), especially if these symptoms are new and frequent (>12 days/month).46 Physicians evaluating women with this constellation of symptoms must be cognizant of the possibility that ovarian pathology may be causing these symptoms.48 However, some evidence suggests that the screening test using these symptoms is not as sensitive or specific as necessary, especially in those with early-stage disease.29,49,50

An ongoing trial is assessing screening for ovarian cancer (UK Collaborative Trial of Ovarian Cancer Screening [UKCTOCS]) using multimodality screening with ultrasound and cancer antigen 125 (CA-125) versus either ultrasound alone or no screening.51 Preliminary results suggest that multimodality screening is more effective at detecting early-stage cancer.52 However, a large randomized trial in more than 78,000 women (the Prostate, Lung, Colorectal, and Ovarian [PLCO] Cancer trial) in the United States found that screening with transvaginal ultrasonography and CA-125 did not decrease mortality from ovarian cancer.53-55 In addition, false-positive results led to serious complications in some women (n = 163) in the PLCO trial. Another study—comparing 1) CA-125 alone; 2) ultrasound with CA-125; or 3) ultrasound alone—found that CA-125 did not increase the detection of cancer over ultrasound alone and that ultrasound was superior to CA-125 alone.56

Randomized data do not yet support routine screening for ovarian cancer in the general population, and routine screening is not currently recommended by any professional society.29,48,53,57-63 Some physicians follow women with high-risk factors (eg, those with BRCA mutations, those with a family history) using CA-125 monitoring and endovaginal ultrasound;51 however, prospective validation of these tests remains elusive. An intriguing study suggests that ovarian cancer is associated with unique odors that can be detected.64-66

A recent screening trial assessed an algorithm that used age and longitudinal changes in CA-125 levels to determine whether women at average risk would develop ovarian cancer (Risk of Ovarian Cancer Algorithm [ROCA]); women deemed at risk were referred for transvaginal sonography.67,68 However, until data from larger randomized controlled trials are published (eg, UKCTOCS), there is not enough evidence to support this screening approach for low-risk women.59,60 Some feel that the ROCA may be useful for high-risk women (eg, those with BRCA mutations). The Society of Gynecologic Oncology (SGO), the FDA, and the Mayo Clinic have stated that the OVA1 test should not be used as a screening tool to detect ovarian cancer (http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/57492) (https://www.sgo.org/newsroom/position-statements-2/multiplex-serum-testing-for-women-with-pelvic-mass/). The OVA1 test uses 5 markers (including transthyretin, apolipoprotein A1, transferrin, beta-2 microglobulin, and CA-125) to assess who should undergo surgery by an experienced gynecologic oncologist and who can have surgery in the community. Based on data documenting an increased survival,
NCCN Panel Members recommend that all patients should undergo surgery by an experienced gynecologic oncologist (category 1).48,69-72 NCCN Panel Members believe that the OvaSure screening test should not be used to detect ovarian cancer.73-76 The OvaSure test uses 6 biomarkers, including leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA-125.77 Recent data show that several markers (including CA-125, HE4, mesothelin, B7-H4, decoy receptor 3 [DcR3], and spondin-2) do not increase early enough to be useful in detecting early-stage ovarian cancer.78-80

**Staging**

The NCCN Guidelines for Ovarian Cancer reflect the importance of stage and grade of disease on prognosis and treatment recommendations. Ovarian cancer is classified primarily as stages I to IV using the FIGO (International Federation of Gynecology and Obstetrics) and AJCC staging systems (see Table 1).81 Most patients present with stage III disease.82 Pathologic grading is an important prognostic factor and is used in the selection of therapy, primarily for early-stage disease. Grading is labeled as 1, 2, or 3. Except for those women with stage I, grade 1 tumors (in whom survival is greater than 95% after comprehensive laparotomy), patients in all other stages of ovarian cancer should be encouraged to enter clinical trials for both primary and recurrence therapy. Primary peritoneal adenocarcinoma is staged using the ovarian cancer staging system (see Table 1).81 Fallopian tube carcinomas are staged using a separate FIGO and AJCC staging system (see Table 2).81

FIGO recently updated the staging for ovarian, fallopian tube, and peritoneal cancer; their new staging system has been approved by the AJCC.82 However, the next edition of the AJCC staging manual (8th edition) will not be published until 2016. The SGO has a statement about the new FIGO staging system (https://www.sgo.org/clinical-practice/guidelines/new-figo-ovarian-cancer-staging-guidelines/). The current guidelines from the College of American Pathologists (CAP) do not include the new FIGO staging system (http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2013/Ovary_13protocol_3200.pdf).

**Caveat**

By definition, the NCCN Practice Guidelines cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment or individualization of treatments. Exceptions to the rule were discussed among panel members during the process of developing these guidelines. A 5% rule (omitting clinical scenarios that comprise less than 5% of all cases) was used to eliminate uncommon clinical occurrences or conditions from these guidelines.

**Epithelial Ovarian Cancer**

**Recommended Workup**

The NCCN Guidelines for Epithelial Ovarian Cancer begin with the management of an undiagnosed pelvic mass or a prior diagnosis of a malignant epithelial ovarian tumor. Many patients with this diagnosis come to NCCN Member Institutions after having had previous surgery.

**Undiagnosed Pelvic Mass**

The primary workup should include an ultrasound and/or abdominal/pelvic CT/MRI scan (after an abdominal/pelvic examination) and appropriate laboratory studies for a patient with a suspicious pelvic mass (detected on abdominal/pelvic exam) and/or ascites, abdominal distention, and/or symptoms (ie, bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, urinary symptoms) without other obvious sources of malignancy (see Workup in the NCCN Guidelines for Epithelial Ovarian Cancer).46,83-89 Tumor markers (including CA-125,
inhibin, alpha-fetoprotein [AFP], and beta–human chorionic gonadotropin [beta-HCG]) can be measured if clinically indicated.\textsuperscript{90-92} Ultrasound is typically used for initial evaluation; however, CT is useful to assess for metastases.\textsuperscript{84} MRI may be useful for determining malignant potential if ultrasound is not reliable.\textsuperscript{88,89} PET/CT scan may be useful for indeterminate lesions.\textsuperscript{93-95}

If possible, fine-needle aspiration (FNA) should be avoided for diagnosis of ovarian cancer in patients with presumed early-stage disease to prevent rupturing the cyst and spilling malignant cells into the peritoneal cavity; however, FNA may be necessary in patients with bulky disease who are not surgical candidates.\textsuperscript{96-98} Other cancers that should be ruled out include bowel, uterine, and pancreatic cancers or lymphoma;\textsuperscript{99,100} benign ovarian and non-ovarian conditions also need to be ruled out (eg, serous cystadenoma).\textsuperscript{101}

It has been suggested that specific biomarkers (serum HE4 and CA-125) along with an algorithm (Risk of Ovarian Malignancy Algorithm [ROMA]) may be useful for determining whether a pelvic mass is malignant or benign.\textsuperscript{102} The FDA has approved the use of HE4 and CA-125 for estimating the risk for ovarian cancer in women with a pelvic mass. Currently, the NCCN Panel does not recommend the use of these biomarkers for determining the status of an undiagnosed pelvic mass.\textsuperscript{103-105} Both primary peritoneal and fallopian tube cancers are usually diagnosed postoperatively (if there is no major involvement of the ovary) or preoperatively (if there is a biopsy and the patient has already had a bilateral oophorectomy). Primary peritoneal and fallopian tube cancers are treated in the same manner as epithelial ovarian cancer. Although there is no direct evidence that chest imaging is necessary, panel members felt that it should be part of the overall evaluation of a patient before surgical staging. Additional diagnostic studies, such as gastrointestinal tract evaluation, are not routinely recommended, although they could prove useful in specific clinical situations.

**Prior Diagnosis of Malignancy**

Patients are often referred to NCCN Member Institutions after having a previous diagnosis of ovarian cancer by surgery or tissue biopsy (cytopathology). Often they have had cytoreductive surgery and comprehensive staging procedures (ie, having met the standards for surgical staging of the Gynecologic Oncology Group [GOG]). However, in some instances, referral occurs after incomplete surgery and/or staging (eg, uterus and/or adnexa intact, omentum not removed, residual disease that is potentially resectable, surgical stage not completely documented). The components of surgical staging are listed in the algorithm (see *Principles of Surgery* in the NCCN Guidelines for Epithelial Ovarian Cancer). Identical workup procedures are recommended for patients having undiagnosed or diagnosed pelvic masses at the time of referral.

Epithelial ovarian cancer has 4 main histologic subtypes (eg, serous, endometrioid, mucinous, clear cell); however, most patients (about 70\%) have serous histology.\textsuperscript{2,81,106-108} Primary treatment for these histologic subtypes does not differ; they are all treated using the recommendations for epithelial ovarian cancer (see the NCCN Guidelines for Epithelial Ovarian Cancer).\textsuperscript{106} However, stage I clear cell carcinoma is treated using recommendations for stage I, grade 3 epithelial ovarian cancer. Recent molecular characterization of clear cell, mucinous, or low-grade tumors suggests that mutations in these histologies are different from those in higher grade tumors. Ovarian cancer can be divided into Types 1 and 2 based on these molecular alterations. It is likely that future research will be based on these findings. At present, treatment of these histologies utilizing alternative
chemotherapy regimens or targeted agents should be performed on clinical trials, which are strongly encouraged for these subgroups.

Pathology review at NCCN Member Institutions is recommended for all patients. The CAP Protocol for the Examination of Specimens from Patients with Carcinoma of the Ovary is a useful tool for pathology reports (http://www.cap.org/apps/docs-committees/cancer/cancer_protocols/2013/Ovary_13protocol_3200.pdf).

Primary Treatment

Primary treatment for presumed ovarian cancer consists of appropriate surgical staging and cytoreduction, followed in most (but not all) patients by systemic chemotherapy. Initial surgery should be a comprehensive staging laparotomy, including a total abdominal hysterectomy (TAH) and bilateral salpingo-oophorectomy (BSO) (see the Principles of Surgery in the NCCN Guidelines for Ovarian Cancer). Based on published improved outcomes, it is recommended (category 1) that a gynecologic oncologist perform the primary surgery. For a young patient who wishes to maintain fertility, a unilateral salpingo-oophorectomy (USO) (preserving the uterus and contralateral ovary) may be adequate for select stage I tumors (stage 1A and 1C, but not stage 1B) and/or low-risk ovarian tumors (ie, early-stage, low-grade invasive tumors; ovarian LMP tumors).

Comprehensive surgical staging should still be performed to rule out occult higher-stage disease, because data show that approximately 30% of patients undergoing complete staging surgery are upstaged. In select patients, minimally invasive procedures may be used for surgical staging. In early-stage disease, minimally invasive techniques to achieve the surgical goals may be considered in selected patients if performed by an experienced gynecologic oncologist. Surgeons tend to use an open method for patients with more widespread disease. Minimally invasive techniques may be considered for prophylactic salpingo-oophorectomy.

Cytoreductive Surgery

Cytoreductive surgery is the initial treatment recommendation for patients with clinical stage II, III, or IV disease (see Primary Treatment in the NCCN Guidelines for Epithelial Ovarian Cancer). Although cytoreductive surgery is the standard of care, this recommendation is based on retrospective data (and thus is not a category 1 recommendation). In general, the procedures outlined in the next paragraph should be part of the surgical management of patients with ovarian, fallopian tube, or primary peritoneal cancer in an effort to fully stage and to achieve maximal cytoreduction to less than 1-cm residual disease or resection of all visible disease in appropriate circumstances. Surgical cytoreduction is optimal if the residual tumor nodules are less than 1 cm in maximum diameter or thickness; extensive resection of upper abdominal ovarian metastases is recommended for patients who can tolerate this surgery. In select patients, minimally invasive procedures may be used to assess whether cytoreductive surgery is feasible and to achieve cytoreduction.

A maximal effort should be made to remove all gross disease. On entering the abdomen, aspiration of ascites or peritoneal lavage should be performed for cytologic examinations. For obvious disease beyond the ovaries, cytologic assessment of ascites and/or lavage specimens will not alter stage or management. Hysterectomy and BSO should be performed. Although total hysterectomy is recommended for most patients, a supracervical hysterectomy is appropriate in some circumstances. An encapsulated mass should be removed intact, if possible. All involved omentum should be removed. Suspicious
and/or enlarged nodes should be resected, if possible.\textsuperscript{137,138} Those patients with tumor nodules, outside the pelvis, of 2 cm or less (presumed stage IIIB) should have bilateral pelvic and para-aortic lymph node dissection (see \textit{Principles of Surgery} in the NCCN Guidelines for Epithelial Ovarian Cancer). For young patients who will abruptly enter menopause after surgery, various supportive care measures are available to decrease hot flashes and other symptoms.\textsuperscript{139-141}

In patients with advanced ovarian cancer who have had complete debulking, data indicate that overall survival is increased in those who receive systematic lymphadenectomy.\textsuperscript{142} Patients with low-volume residual disease after surgical cytoreduction for invasive epithelial ovarian or peritoneal cancer are potential candidates for intraperitoneal (IP) therapy.\textsuperscript{143} In these patients, consideration should be given to placement of an IP catheter with initial surgery.\textsuperscript{109} Procedures that may be considered for optimal surgical cytoreduction (in all stages) include: radical pelvic dissection, bowel resection, diaphragm or other peritoneal surface stripping, splenectomy, partial hepatectomy, cholecystectomy, partial gastrectomy or cystectomy, ureteroneocystostomy, distal pancreatectomy, or appendectomy.\textsuperscript{126,134,144}

\textbf{Neoadjuvant Chemotherapy}

The therapeutic benefit of neoadjuvant chemotherapy followed by interval cytoreduction remains controversial (see next paragraph).\textsuperscript{128,145-150} It may be considered (category 1) for patients with bulky stage III to IV disease who are not surgical candidates; however, a gynecologic oncologist should make this assessment before neoadjuvant chemotherapy is administered.\textsuperscript{151-156} Standard intravenous regimens described in the algorithm may be used for neoadjuvant chemotherapy (see \textit{Principles of Chemotherapy} in the NCCN Guidelines for Ovarian Cancer). Before initiation of chemotherapy, the pathologic diagnosis should be confirmed (by FNA, biopsy, or paracentesis) in this group of patients. \textit{Neoadjuvant therapy} refers to treatment (eg, drugs, radiation, or other treatment) that is given to reduce the tumor burden before cancer surgery (see \textit{Principles of Chemotherapy} in the NCCN Guidelines for Epithelial Ovarian Cancer).

A randomized phase III trial assessed neoadjuvant chemotherapy with interval debulking surgery versus upfront primary debulking surgery in patients with extensive-stage IIIC/IV ovarian, primary peritoneal, and fallopian tube carcinoma (sponsored by the EORTC-GCG and the NCIC-CTG).\textsuperscript{151} Median overall survival was equivalent in these patients (29 vs. 30 months), but patients receiving neoadjuvant chemotherapy with interval debulking surgery had fewer complications.

A major criticism of this international trial is that reported progression-free survival (PFS) and overall survival were inferior to those reported more recently in randomized studies in the United States of patients undergoing primary debulking surgery followed by postoperative intravenous chemotherapy for advanced ovarian cancer (overall survival averages about 50 months).\textsuperscript{143,156} Although the median overall survival in the international trial is 20 months lower than that reported in U.S. trials using the customary sequence of therapeutic interventions (ie, primary debulking surgery followed by chemotherapy), this difference may have been a result of selection of higher-risk patients to the international trial (which did not include patients with stage IIIB or earlier-stage cancer). Also, primary or interval debulking surgery in the international trial may not have been optimal (ie, patients may have had >1 cm of residual disease).\textsuperscript{128}

In the opinion of the subcommittee for the NCCN Guidelines for Ovarian Cancer, more data will be necessary prior to recommending neoadjuvant chemotherapy in potentially resectable ovarian cancer patients, and upfront debulking surgery remains the treatment of choice.
in the United States. Note that the authors of the international trial believe that upfront debulking surgery should remain the standard of care for stage IIIB or earlier-stage patients but that neoadjuvant chemotherapy with interval debulking surgery is an option for patients with extensive-stage IIIC/IV disease.

**Incompletely Staged Patients**

For patients with incomplete previous surgery and/or staging, treatment recommendations are outlined in the algorithm (see Diagnosis by Previous Surgery in the NCCN Guidelines for Epithelial Ovarian Cancer). For patients with stage II to IV disease who have residual disease that is considered unresectable, consider completion surgery after 3 to 6 cycles of chemotherapy. Depending on the surgical results, patients would then receive postoperative chemotherapy. Tumor reductive surgery is recommended for all patients with stage II to IV disease with suspected residual disease that is potentially resectable.

**Chemotherapy**

Most patients with epithelial ovarian cancer receive postoperative systemic chemotherapy, which is also referred to as adjuvant therapy (see Principles of Chemotherapy in the NCCN Guidelines for Epithelial Ovarian Cancer). Observation, however, is recommended for patients with stage IA or IB, grade 1 tumors, because survival is greater than 90% for this group with surgical treatment alone. If observation (without the addition of chemotherapy) is considered for stage IA or IB, grade 2 tumors, a surgical staging procedure is recommended for all patients. Recommendations regarding initial primary chemotherapy/primary adjuvant therapy include intravenous with [or without] IP options (see Primary Chemotherapy/Primary Adjuvant Chemotherapy Regimens for Stage II–IV in the NCCN Guidelines for Epithelial Ovarian Cancer). All of the regimens (including the combined intravenous/IP chemotherapy) may be used for epithelial ovarian, primary peritoneal, and fallopian tube cancers. The intravenous/IP chemotherapy regimen (IP chemotherapy) is recommended for stage III patients with optimally debulked (<1 cm residual) disease based on randomized controlled trials (category 1) (http://www.cancer.gov/clinicaltrials/conducting/developments/ipchemo-digest/Page1).

Stage II patients may also receive IP chemotherapy, although no randomized evidence for stage II has been published.

In women with stage III cancer, survival was increased by 16 months after IP therapy using cisplatin/paclitaxel when compared with standard intravenous therapy (65.6 vs. 49.7 months, *P* = .03) in the GOG 172 trial. For patients for whom this does not apply (eg, those with poor performance status [PS]), the combination of intravenous paclitaxel plus carboplatin (category 1) may be used (see Primary Chemotherapy/Primary Adjuvant Therapy in the NCCN Guidelines for Epithelial Ovarian Cancer). Intravenous docetaxel plus carboplatin (category 1) or paclitaxel plus cisplatin (category 1) are options for alternative regimens. The docetaxel/carboplatin regimen may be considered for patients who are at high risk for neuropathy (eg, patients with diabetes). Recommendations for the number of cycles of treatment vary with the stage of the disease. For patients with advanced-stage disease (stages II–IV), 6 to 8 cycles of chemotherapy are recommended, whereas 3 to 6 cycles are recommended for earlier-stage disease. Some clinicians feel there is a potential survival advantage for 6 cycles of chemotherapy in patients with serous cytology.

The recommended intravenous regimens accepted by a consensus of the NCCN Panel include: 1) paclitaxel, 175 mg/m² over 3-hour intravenous infusion, followed by carboplatin, dosed at an area under the curve (AUC) of 5 to 7.5 intravenous over 1 hour on day 1, given...
every 3 weeks for 6 cycles (category 1);\textsuperscript{164,169} 2) dose-dense paclitaxel, 80 mg/m\textsuperscript{2} intravenous over 1 hour on days 1, 8, and 15 plus carboplatin AUC 6 intravenous over 1 hour on day 1, every 3 weeks for 6 cycles (category 1);\textsuperscript{170} 3) docetaxel, 60 to 75 mg/m\textsuperscript{2} 1-hour intravenous infusion followed by carboplatin, dosed at AUC of 5 to 6 intravenous over 1 hour on day 1, every 3 weeks for 6 cycles (category 1).\textsuperscript{165} Note that carboplatin dosing may be revised based on changes in serum creatinine methodology (http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProducts andTobacco/CDER/ucm228974.htm). These intravenous regimens may also be used for neoadjuvant chemotherapy (see Principles of Chemotherapy in the NCCN Guidelines for Ovarian Cancer).

The recommended IP chemotherapy regimen is paclitaxel, 135 mg/m\textsuperscript{2} continuous intravenous infusion over 3 or 24 hours on day 1; cisplatin, 75 to 100 mg/m\textsuperscript{2} IP on day 2 after intravenous paclitaxel; paclitaxel, 60 mg/m\textsuperscript{2} IP on day 8; repeat every 3 weeks for 6 cycles (category 1).\textsuperscript{143} The published randomized trial for this IP/intravenous regimen used intravenous continuous infusion of paclitaxel over 24 hours. A 3-hour infusion of paclitaxel has not been proven to be equivalent to a 24-hour infusion, although a 3-hour infusion has been reported to be more convenient, easier to tolerate, and less toxic.\textsuperscript{171} Note that these IP regimens include intravenous regimens so that systemic disease can also be treated.

These regimens have different toxicity profiles. The docetaxel/carboplatin regimen is associated with increased risk for neutropenia; the intravenous paclitaxel/carboplatin regimen is associated with sensory peripheral neuropathy, and dose-dense paclitaxel is associated with increased anemia.\textsuperscript{165,169,170} The IP paclitaxel/cisplatin regimen is associated with leukopenia, infection, fatigue, renal toxicity, abdominal discomfort, and neurotoxicity.\textsuperscript{172,173} In the initial studies, only 42% of women were able to complete all 6 treatment cycles (of the IP regimen) because of toxicity; however, with more experience, this percentage has improved in the major cancer centers.\textsuperscript{174} Using a lower IP cisplatin dose of 75 mg/m\textsuperscript{2} or splitting the dose may help to decrease toxicity.\textsuperscript{171,174,175} This approach is currently under investigation in an ongoing GOG clinical trial.

Patients considered for the IP cisplatin and IP/intravenous paclitaxel regimen should have normal renal function before starting, a medically appropriate PS based on the future toxicities of the IP/intravenous regimen, and no previous evidence of medical problems that could significantly worsen during chemotherapy (eg, preexisting neuropathy) (see Principles of Chemotherapy in the NCCN Guidelines for Epithelial Ovarian Cancer). Reasons for discontinuing the IP regimen included catheter complications, nausea/vomiting/dehydration, and abdominal pain.\textsuperscript{176} Women unable to complete IP therapy should receive intravenous therapy. Techniques to decrease catheter complications include catheter choice and timing of insertion.\textsuperscript{162,177} Expert nursing care may help to decrease complications.\textsuperscript{161} Giving intravenous hydration before and after IP chemotherapy is a useful strategy to prevent renal toxicity.\textsuperscript{174} After chemotherapy, patients often require intravenous fluids (5–7 days) in the outpatient setting to prevent or help treat dehydration. Whether to use IP or intravenous chemotherapy remains controversial.\textsuperscript{176,178-181}

Patients with poor PS, comorbidities, stage IV disease, or advanced age (>65 years) may not tolerate the IP regimen or the other combination intravenous regimens described in the NCCN Guidelines. Single-agent platinum agents, such as cisplatin or carboplatin, may be more appropriate for these patients. Algorithms are available for predicting chemotherapy toxicity (see the NCCN Guidelines for Senior Adult Oncology). The IP regimen published by Armstrong et al has,
however, documented the longest median survival (65.6 months) that has been described to date in optimally debulked stage III patients.\(^{143,182}\) A recent study reported overall survival of 110 months in patients with stage III ovarian cancer and no residual disease who received the IP regimen.\(^{182}\) Patients with primary peritoneal cancer, fallopian tube cancer, or MMMT can also be considered for IP chemotherapy.\(^{163,177}\) All women should be counseled about the clinical benefit associated with combined intravenous and IP chemotherapy administration before undergoing surgery for epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, or MMMT. A recent study reported that women with aberrant \(BRCA1\) expression had increased survival when treated with IP cisplatin/paclitaxel.\(^{183}\)

Dose-dense weekly paclitaxel with carboplatin has been shown to increase both PFS (28 vs. 17 months, \(P = .0037\)) and overall survival when compared with standard therapy given every 3 weeks (ie, intravenous carboplatin/paclitaxel) in women with advanced epithelial ovarian cancer.\(^{170,184}\) In the dose-dense group, median overall survival was 100.5 months versus 62.2 months in the conventional treatment group (HR 0.79, 95% CI 0.63–0.99; \(P = .039\)).\(^{185}\) However, the dose-dense regimen is more toxic, and patients discontinued dose-dense paclitaxel therapy more often than did those receiving standard therapy. Future studies will compare the effect of weekly paclitaxel on the overall survival benefit with that of using IP chemotherapy.\(^{186}\)

**Anti-Angiogenesis Agents**

A recent phase III randomized trial (GOG 0218) assessed bevacizumab combined with carboplatin/paclitaxel in the upfront setting compared to carboplatin/paclitaxel alone. The median PFS was significantly increased (14.1 vs. 10.3 months, \(P < .001\)) in patients receiving prolonged bevacizumab (upfront and as maintenance therapy) when compared with chemotherapy alone.\(^{187,188}\) However, PFS was not significantly increased in patients who did not receive maintenance bevacizumab (upfront with placebo maintenance) versus chemotherapy alone (ie, bevacizumab/carboplatin/paclitaxel vs. carboplatin/paclitaxel). Quality of life was not improved in GOG 0218.\(^{189}\)

Another phase III randomized trial (ICON7) also assessed bevacizumab/carboplatin/paclitaxel in the upfront setting. The trial design of ICON7 differs from GOG 0218 (see next paragraph).\(^{190,191}\) Although the PFS data from ICON7 confirm the findings of GOG 0218, the benefits appear to be modest (2.4-month increase in PFS) and mature survival data have not been reported.\(^{189,190}\)

Panel members had a major disagreement about recommending the addition of bevacizumab to upfront chemotherapy with carboplatin/paclitaxel or using bevacizumab as maintenance therapy, which is reflected in the category 3 recommendations for these regimens (see Primary Chemotherapy/Primary Adjuvant Chemotherapy Regimens for Stage II–IV in the NCCN Guidelines for Epithelial Ovarian Cancer).\(^{192}\) Many panel members believe that bevacizumab should not be added to upfront chemotherapy in patients with ovarian cancer, because data from these 2 phase III randomized trials (ie, GOG 0218, ICON7) have not shown a statistically significant increase in overall survival and/or improved quality of life.\(^{188,189,191,193-195}\) Note that a category 3 recommendation is based on any level of evidence (eg, even phase III randomized trials), but fewer (<50%) panel members agree that the intervention is appropriate.

The NCCN Panel recommends (category 3) that if bevacizumab is used with upfront chemotherapy followed by maintenance therapy, then either the GOG 0218 or ICON7 regimens should be used (see Primary Chemotherapy/Primary Adjuvant Chemotherapy Regimens for Stage II–
IV in the NCCN Guidelines for Epithelial Ovarian Cancer). The only GOG 0218 regimen that is recommended (category 3) is the prolonged bevacizumab regimen (upfront with carboplatin/paclitaxel followed by maintenance bevacizumab). This topic is discussed in greater detail in the recently published NCCN Guidelines Insights: Ovarian Cancer. The NCCN Panel encourages participation in ongoing clinical trials that are further investigating the role of anti-angiogenesis agents in the treatment of ovarian cancer, both in the upfront and recurrence settings.

Number of Chemotherapy Cycles and Agents

Panel members had an extensive discussion about the number of cycles of chemotherapy that should be recommended for patients with advanced-stage disease. There is no evidence confirming that more than 6 to 8 cycles of combination chemotherapy are required for initial chemotherapy. Patients can also have 3 to 6 cycles of chemotherapy followed by completion surgery and then postoperative chemotherapy (see Primary Treatment in the NCCN Guidelines for Epithelial Ovarian Cancer). The role of maintenance (or postremission) therapy in patients who achieve a complete clinical remission after 6 to 8 cycles of chemotherapy is an option based on the results from GOG 178. This trial randomly assigned patients to 3 versus 12 months of further paclitaxel (135–175 mg/m² every 4 weeks for 12 cycles) after initial chemotherapy. The published study treated patients at 175 mg/m²; the plan was to decrease the dose to 135 mg/m², but the protocol closed before any patients were treated at the lower dose. The results of this trial suggest that patients receiving 12 months of therapy sustained a PFS advantage. However, postremission paclitaxel chemotherapy is a category 3 recommendation because it is associated with toxicity and it only increased PFS. Another study suggests that postremission paclitaxel is not beneficial.

Drug Reactions

Virtually all drugs have the potential to cause drug reactions, either during or after the infusion. Drugs used in gynecologic oncology treatment that more commonly cause adverse reactions include carboplatin, cisplatin, docetaxel, liposomal doxorubicin, oxaliplatin, and paclitaxel. Drug reactions can occur with either intravenous or IP administration of these drugs. Most of these drug reactions are mild infusion reactions (ie, skin reactions, cardiovascular reactions, respiratory or throat tightness), but more severe allergic reactions (ie, life-threatening anaphylaxis) can occur. Infusion reactions are more common with paclitaxel, but mild reactions can also occur with liposomal doxorubicin. Allergic reactions (ie, true drug allergies) are more common with platinum agents (ie, carboplatin, cisplatin, oxaliplatin).

Management of drug reactions is discussed in the NCCN Guidelines for Ovarian Cancer. Algorithms are provided for management of mild, severe, and life-threatening reactions. These drug reaction algorithms are also useful for patients with other gynecologic cancers (eg, cervical and uterine cancers) who are receiving carboplatin, cisplatin, docetaxel, liposomal doxorubicin, oxaliplatin, or paclitaxel. Typically, the infusion should be stopped for patients having a reaction; further management is provided in the algorithms. Standard resuscitation procedures (ie, Advanced Cardiovascular Life Support [ACLS]) should be followed for patients with acute cardiopulmonary arrest. For patients with allergic reactions, various desensitization protocols have been published and should be followed. To maximize safety,
patients may be desensitized in the intensive care unit.\textsuperscript{203} Almost all patients can be desensitized (about 90%).\textsuperscript{203} For severe life-threatening reactions, the implicated agent should not be used again unless under the supervision and guidance of an allergist or specialist with expertise in desensitization. If a mild allergic reaction is suspected, and it is appropriate to administer the drug again, a desensitization regimen should be used even if the symptoms have resolved.\textsuperscript{201} Patients must be desensitized with each infusion if they previously had a drug reaction.\textsuperscript{213-215} Data suggest that an extended infusion schedule and use of premedication may decrease the number of hypersensitivity reactions to carboplatin.\textsuperscript{216} Skin testing is associated with false-negative results.\textsuperscript{217,218}

Radiation Therapy
Whole abdominal radiation therapy is rarely used in NCCN Member Institutions. It is not included as a treatment recommendation in the NCCN Guidelines for Ovarian Cancer. Palliative localized RT is an option for symptom control in patients with recurrent disease (see Acceptable Recurrence Therapies in the NCCN Guidelines for Epithelial Ovarian Cancer).\textsuperscript{219-223} Patients who receive radiation are prone to vaginal stenosis, which can impair sexual function. Women can use vaginal dilators to prevent or treat vaginal stenosis. Dilator use can start 2 to 4 weeks after RT is completed and can be done indefinitely (http://www2.mskcc.org/patient_education/_assets/downloads-english/571.pdf).

Recommendations After Primary Treatment
After initial treatment (eg, 6 cycles of chemotherapy), patients should undergo a clinical re-evaluation. Observation with follow-up is recommended for patients who have no evidence of progression of cancer (ie, complete clinical remission) after initial treatment (see Follow-Up Recommendations in this Discussion) (also see Monitoring/Follow-up in the NCCN Guidelines for Epithelial Ovarian Cancer); other options are discussed below. Patients with partial remission or progression during initial treatment should be treated with second-line approaches (see Recurrent Disease in this Discussion) (see Therapy for Persistent Disease or Recurrence in the NCCN Guidelines for Epithelial Ovarian Cancer).\textsuperscript{224,225}

Options for maintenance treatment—for the management of advanced-stage (stages II–IV) patients who are in complete clinical remission after their initial therapeutic regimen—include observation alone, a clinical trial, or additional chemotherapy\textsuperscript{198} (eg, paclitaxel, category 3), preferably in a controlled clinical trial (see Secondary Adjuvant Therapy in the NCCN Guidelines for Epithelial Ovarian Cancer). If used, the recommended paclitaxel regimen is 135 to 175 mg/m\textsuperscript{2} every 4 weeks for 12 cycles.\textsuperscript{198} Use of maintenance bevacizumab (category 3) is discussed in an earlier section and has been shown to modestly increase PFS when administered following initial chemotherapy that included bevacizumab (see Anti-Angiogenesis Agents in this Discussion). Note that complete clinical remission is defined as no objective evidence of disease (ie, negative physical examination, negative CA-125 levels, negative CT with <1 cm lymph nodes).\textsuperscript{224,225}

Follow-up Recommendations
Recurrent disease may be identified clinically (eg, pelvic pain, weight loss), biochemically (ie, elevated CA-125 levels), and/or with imaging following initial treatment. After the completion of primary surgery and chemotherapy in patients with all stages of ovarian cancer (or fallopian tube cancer or primary peritoneal cancer) who have a complete response, the standard recommendation is observation with follow-up to monitor for recurrent disease. Recommendations for monitoring are described in the algorithm (see Monitoring/Follow-up in the NCCN Guidelines...
Guidelines for Epithelial Ovarian Cancer). Chest/abdominal/pelvic CT, MRI, PET scans (category 2B for PET), PET-CT, and chest imaging may be ordered if clinically indicated.\textsuperscript{226-229} Patients should be educated about the signs and symptoms suggestive of recurrence (eg, pelvic pain, bloating, early satiety, obstruction, weight loss, fatigue). Patients who have had fertility-sparing surgery should be monitored by ultrasound examinations if necessary; completion surgery should be considered (category 2B) after they finish childbearing. Note that a category 2B recommendation is based on lower level evidence (eg, phase II randomized trials) and a majority vote (>50% but <85%) from panel members who agree that the intervention is appropriate.

If the CA-125 level was initially elevated, the measurement of a CA-125 level or other tumor markers at each follow-up evaluation is recommended. A multi-institutional European trial assessed the use of CA-125 for monitoring for ovarian cancer recurrence after primary therapy.\textsuperscript{230-232} The data suggest that treating recurrences early (based on detectable CA-125 levels in asymptomatic patients) is not associated with an increase in survival and is associated with a decrease in quality of life.\textsuperscript{233} Recent recommendations from the SGO state that use of CA-125 levels for surveillance is optional.\textsuperscript{228} The NCCN Panel feels that the European trial has limitations and patients should discuss the pros and cons of CA-125 monitoring with their physicians. In addition, patients seem reluctant to give up monitoring.\textsuperscript{234} Others have discussed this study in greater detail.\textsuperscript{235-237}

**Management of an Increasing CA-125 Level**

The management of patients in a clinical complete remission—who (during routine monitoring and follow-up) are found to have an increasing CA-125 level but no signs or symptoms of recurrent disease (eg, pelvic pain, bloating, obstruction), following an evaluation including a negative pelvic examination and negative chest/abdominal/pelvic CT scans—is somewhat controversial. Patients who have never received chemotherapy (ie, naïve to chemotherapy) should be managed as newly diagnosed patients, should undergo clinically appropriate imaging studies and surgical debulking, and should be treated as previously described (see *Primary Treatment* in the NCCN Guidelines for Epithelial Ovarian Cancer).

Recurrence therapy refers to drugs, radiation, or other treatment that is given to decrease tumor burden, control symptoms, or increase length and/or quality of life for patients with recurrent disease. After the documentation of an increased CA-125 level (ie, biochemical relapse), the median time for a clinical relapse is 2 to 6 months. However, data suggest that immediate treatment for biochemical relapse is not beneficial; therefore, immediate treatment is a category 2B recommendation in the NCCN Guidelines.\textsuperscript{230} After biochemical relapse, recommended options include enrollment in a clinical trial or delaying treatment (ie, observation) until clinical symptoms arise (see *Recurrent Disease* in the NCCN Guidelines for Epithelial Ovarian Cancer).

Because tamoxifen and other hormonally active agents have a defined response rate for patients with recurrent disease who have progressed after platinum-based chemotherapy,\textsuperscript{238} these agents are frequently administered to patients who have only a rising CA-125 level\textsuperscript{239} as evidence of tumor progression.\textsuperscript{240} Tamoxifen, other hormonal agents, or other recurrence therapy are acceptable recommendations for this clinical situation (category 2B for all).

**Recurrent Disease**

The prognosis is poor either 1) for patients who progress after 2 consecutive chemotherapy regimens without ever sustaining a clinical benefit (refractory);\textsuperscript{241} or 2) for those whose disease recurs in less than 6 months (platinum resistant). Note that progression is typically defined using RECIST (Response Evaluation Criteria in Solid Tumor)
Panel members emphasized the importance of clinical trials to identify agents active in this group of patients. Because these patients were resistant to their primary induction regimen, retreatment with a platinum compound or paclitaxel is not generally recommended. Although panel members do not recommend retreatment with platinum agents, they recognize that altering the schedule of paclitaxel may produce secondary responses. Before any drug is given in the recurrent setting, the clinician should be familiar with the drug's metabolism and should make certain that the patient is an appropriate candidate for the drug (eg, that the patient has adequate renal or hepatic function). Clinical judgment must be used when selecting postoperative chemotherapy.

Options for platinum-resistant patients or for those with stages II to IV disease who have a partial response include recurrence therapy (see Acceptable Recurrence Therapies in the NCCN Guidelines for Epithelial Ovarian Cancer), clinical trial, or observation (category 2B for observation). Patients who relapse 6 months or more after initial chemotherapy are termed platinum sensitive. Combination platinum-based chemotherapy is preferred for first recurrence (category 1) in platinum-sensitive patients (see Therapy for Persistent Disease or Recurrence in the NCCN Guidelines for Epithelial Ovarian Cancer). Possible regimens are discussed in the following section (see Acceptable Recurrence Modalities in this Discussion).

Patients with ovarian cancer will often be retreated with multiple courses of recurrence therapy. Caution should be used in patients who receive multiple sequential courses of chemotherapy, because they may experience excessive toxicity and may not be able to tolerate doses used for first-line recurrence therapy; thus, clinical judgment should be used when selecting doses (see Principles of Chemotherapy in the NCCN Guidelines for Epithelial Ovarian Cancer). Potential, ancillary, palliative, surgical and/or supportive care procedures for selected patients are summarized in the algorithm (see Principles of Surgery in the NCCN Guidelines for Epithelial Ovarian Cancer) (http://emedicine.medscape.com/article/270646-overview#aw2aab6b4). The SGO has a position statement on Principles of Palliative Care (https://www.sgo.org/newsroom/position-statements-2/delivery-of-palliative-care-services/).

Secondary cytoreductive surgery can be considered for patients who recur (ie, radiographic and/or clinical relapse) after a long disease-free interval (6 months or more). A recent meta-analysis suggests that survival increases for patients with recurrent disease who have complete cytoreduction. The duration of the disease-free interval has not been established, although panel members agreed that it should be at least 6 months before surgery should be considered.

Acceptable Recurrence Modalities
The NCCN Panel felt that no single therapeutic agent should be currently recommended as the treatment of choice for recurrent ovarian carcinoma. However, some agents are preferred based on expert opinion primarily for reasons of decreased toxicity and/or marginally increased effectiveness (see Acceptable Recurrence Therapies in the NCCN Guidelines for Epithelial Ovarian Cancer). A meta-analysis of chemotherapy for recurrent ovarian cancer was published in 2007. Recurrence therapy refers to therapy (eg, drugs, radiation, or other treatment) that is given for recurrent cancer to control symptoms and increase length or quality of life for clinical, biochemical, or radiographic evidence of recurrent cancer following initial treatment.

The consensus of the NCCN Panel for the treatment of recurrent disease is shown in the algorithm (see Acceptable Recurrence Therapies in the NCCN Guidelines for Epithelial Ovarian Cancer).
Platinum-based combination chemotherapy is recommended (category 1) for platinum-sensitive recurrence (see Therapy for Persistent Disease or Recurrence in the NCCN Guidelines for Epithelial Ovarian Cancer). Preferred combinations for platinum-sensitive recurrent disease include carboplatin/paclitaxel (category 1), carboplatin/weekly paclitaxel, carboplatin/docetaxel, carboplatin/gemcitabine (which has been shown to improve PFS), carboplatin/liposomal doxorubicin (also has been shown to improve PFS), or cisplatin/gemcitabine.

For platinum-resistant disease, the preferred single agent is a non-platinum–based agent (ie, docetaxel, oral etoposide, gemcitabine, liposomal doxorubicin, weekly paclitaxel, topotecan); sequential therapy using single agents is typically used. The response rate of the following agents appears to be similar: topotecan, 20%; gemcitabine, 19%; liposomal doxorubicin, 26%; and oral etoposide, 27%. In platinum-resistant patients, the response rate for docetaxel is 22% and for weekly paclitaxel is 21%. For platinum-sensitive disease in patients who cannot tolerate combination therapy, the preferred single agent is carboplatin or cisplatin. Recent reports suggest that weekly topotecan is less toxic than the daily regimen.

Other potentially active agents include altretamine, capecitabine, cyclophosphamide, doxorubicin, ifosfamide, irinotecan, melphalan, oxaliplatin, paclitaxel, nanoparticle albumin-bound paclitaxel (ie, nab-paclitaxel), pemetrexed, and vinorelbine (see Acceptable Recurrence Therapies in the NCCN Guidelines for Epithelial Ovarian Cancer). Nab-paclitaxel has an overall response rate of 64%. Vinorelbine has a response rate of 20%. Altretamine has a 14% response rate and ifosfamide has a 12% response rate, although less information regarding their use in paclitaxel-refractory patients is available. In platinum-resistant patients, the response rate for pemetrexed is 21%. Bevacizumab is also active (21%) in both platinum-sensitive and platinum-resistant patients, although it may cause hypertension, arterial thrombosis, or intestinal perforation.

Several phase III randomized trials have recently assessed combination therapy with bevacizumab for recurrent ovarian cancer (ie, AURELIA, OCEANS). Based on the results of the AURELIA trial, the NCCN panel now recommends the following combination regimens for patients with platinum-resistant recurrent ovarian cancer: weekly paclitaxel/bevacizumab, liposomal doxorubicin/bevacizumab, and topotecan/bevacizumab. These bevacizumab combination regimens are contraindicated in patients at increased risk of gastrointestinal perforation or those who have previously received bevacizumab. Previously, only single-agent therapy was recommended for platinum-resistant disease.

A phase III randomized trial (OCEANS) assessed carboplatin/gemcitabine with and without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer who had not previously received bevacizumab. In the OCEANS trial, PFS was increased in patients receiving the chemotherapy/bevacizumab arm when compared with chemotherapy alone (12.4 vs. 8.4 months, \( P < .0001 \)). Combination therapy with bevacizumab is a category 2B recommendation for platinum-sensitive disease, because there is less consensus among the NCCN Panel (>50% but < 85%) that this intervention is appropriate. Panel members feel other combination regimens may be preferred for platinum-sensitive disease than those with bevacizumab. In addition, the carboplatin/gemcitabine/bevacizumab regimen is only recommended in patients who have not previously received bevacizumab. Based on phase II trials, panel members feel that bevacizumab alone is useful in patients who have recurrent disease (especially those with ascites),...
which is reflected in the category 2A recommendation for single-agent bevacizumab.\textsuperscript{264,286,287,293}

Taxanes (including docetaxel and paclitaxel) and platinum compounds (including cisplatin, carboplatin, and oxaliplatin) can be used in appropriate patients.\textsuperscript{198,246,270,294} Capecitabine has activity in patients resistant to platinum and taxanes.\textsuperscript{295} Other alkylating agents, including cyclophosphamide and melphalan, can also be used.\textsuperscript{166,296} In addition, for patients who cannot tolerate or have not responded to cytotoxic regimens, hormonal therapy with tamoxifen or other agents (including anastrozole, letrozole, leuprolide acetate, or megestrol acetate) continues to be a viable therapeutic option.\textsuperscript{297-302}

Recent data suggest that olaparib (AZD2281), which is a PARP (poly ADP-ribose polymerase) inhibitor, is active in select patients (those with \textit{BRCA1} and \textit{BRCA2} mutations have higher response rates than \textit{BRCA}-negative patients) with chemotherapy-refractory ovarian cancer, especially those with platinum-sensitive disease.\textsuperscript{264,303-307} Patients who are resistant or refractory to platinum have a lower response rate to olaparib.\textsuperscript{303,305,306} A phase II study found that olaparib was similar to pegylated liposomal doxorubicin. Note that olaparib is not FDA approved for this indication and is only available in a clinical trial. Localized RT can also provide effective palliation when radiation ports are tailored to specific symptomatic disease sites.\textsuperscript{219,220}

Chemotherapy/resistance assays and/or other biomarker assays are being used in some NCCN Member Institutions to aid in selecting chemotherapy in situations where there are multiple equivalent chemotherapy options available; however, the current level of evidence (category 3) is not sufficient to supplant standard-of-care chemotherapy.\textsuperscript{308,309} Thus, the NCCN Panel felt that in vitro chemosensitivity testing to choose a chemotherapy regimen for recurrent disease situations should not be recommended (category 3), owing to the lack of demonstrable efficacy for such an approach. ASCO also does not recommend use of chemotherapy sensitivity and resistance assays, unless in a clinical trial setting.\textsuperscript{310}

However, regardless of which regimen is selected initially, reevaluation should follow after 2 to 4 cycles of chemotherapy (depending on the agent) to determine if patients benefited from chemotherapy. Patients who primarily progress on 2 consecutive chemotherapy regimes without evidence of clinical benefit may not benefit from additional therapy.\textsuperscript{241} Decisions to offer supportive care, additional therapy, or clinical trials should be made on a highly individual basis.

**Less Common Ovarian Histopathologies**

**Overview**

Less common histopathologies of ovarian cancer include: malignant germ cell neoplasms, carcinosarcomas (MMMTs), malignant sex cord-stromal tumors, and ovarian LMP tumors. These tumors account for approximately 5% of all ovarian cancers and differ from epithelial ovarian cancer in their biology and recommended approaches to treatment. In contrast to epithelial ovarian cancer, many patients with these tumors present at an early stage and tumors may be confined to one ovary; thus, some of these patients are candidates for fertility-sparing surgery, which may be done laparoscopically (see \textit{Principles of Surgery} in the NCCN Guidelines for Epithelial Ovarian Cancer).\textsuperscript{311} The diagnosis of less common ovarian histopathologies (LCOH) is often not made until after surgery.

**Recommended Workup**

Patients may obtain consultation at an NCCN Member Institution for recommendations and treatment of an undiagnosed pelvic mass, or for
management of a previously biopsied malignant ovarian tumor. Many such patients come to NCCN Member Institutions after having had previous surgery at other institutions. Patients having a histologically undiagnosed pelvic mass should undergo evaluation and staging as described in the algorithm (see Workup in the NCCN Guidelines for Less Common Ovarian Histopathologies). The workup for LCOH is similar to the workup for ovarian cancer. Tumor markers (including CA-125, inhibin, AFP, and beta-HCG) can be measured if clinically indicated. Women younger than 35 years with a pelvic mass should have AFP levels measured to assess for germ cell tumors.90-92

Patients desiring to potentially maintain fertility should have an intraoperative frozen section evaluation. Fertility-sparing surgery may be performed (if technically feasible) if the frozen section results are positive for malignant germ cell tumor, ovarian cancer of LMP, or clinical stage I epithelial ovarian or stromal tumors.112,113,116,312-315 Patients who do not desire fertility preservation; those who have a clinical stage II, III, or IV epithelial ovarian cancer or stromal tumor; or those with carcinosarcoma (MMMT) should undergo comprehensive surgical staging as per the ovarian cancer guidelines (see Principles of Surgery in the NCCN Guidelines for Ovarian Cancer).

Patients may have been referred to an NCCN Member Institution after receiving a diagnosis of an LCOH tumor. The recommended initial surgical recommendation depends on the specific histologic diagnosis. Often, patients have been comprehensively staged (having met the standards for surgical staging of the GOG) and have undergone cytoreductive surgery. However, in some instances, they are referred after having had incomplete staging (ie, uterus and/or adnexa intact, omentum not removed, surgical stage not documented).

Malignant Germ Cell Tumors

These tumors include dysgerminomas, immature teratomas, embryonal tumors, and endodermal sinus (yolk sac) tumors; they mainly occur in younger women who are often diagnosed with stage I disease.316,317 The recommended workup (see Recommended Workup as previously discussed) for malignant germ cell tumors may include pulmonary function studies if bleomycin is being considered.90,318 In young women (<35 years) with a pelvic mass, AFP levels can indicate the presence of germ cell tumors.90-92 Malignant germ cell tumors have an excellent prognosis. After appropriate treatment, 5-year survival is more than 85%.316,319,320

Treatment

Completion surgery with comprehensive staging is recommended as initial surgery for patients who do not desire fertility preservation. The staging system for ovarian and primary peritoneal cancer is also used for malignant germ cell tumors (see Table 1). After comprehensive surgical staging, observation is recommended for patients with stage I dysgerminoma or immature teratoma.321 Surgery for young adult or pediatric patients may differ from that for adult patients (see Principles of Surgery in the NCCN Guidelines for Ovarian Cancer). In pediatric or adolescent patients with early-stage germ cell tumors, comprehensive staging may be omitted.322,323 If these patients have had incomplete surgical staging, recommended options depend on the type of tumor, the results of imaging and tumor marker testing (eg, AFP, beta-HCG), the age of the patient, and whether the patient desires fertility preservation (see Malignant Germ Cell Tumors in the NCCN Guidelines for Less Common Ovarian Histopathologies).

Fertility-sparing surgery should be considered for those desiring fertility preservation, regardless of stage (see Primary Treatment for Malignant Germ Cell Tumors in the NCCN Guidelines for Less Common Ovarian
Histopathologies).\textsuperscript{116,317,320,324-326} Patients who chose fertility-sparing surgery should be monitored by ultrasound examinations if necessary; completion surgery (category 2B) should be considered after finishing childbearing.

After surgery, surveillance is the recommended option for patients with stage I dysgerminoma or stage I, grade I immature teratoma based on European and pediatric reports,\textsuperscript{327-330} observation or chemotherapy may be considered for select stage IA tumors (see the NCCN Guidelines for Malignant Germ Cell Tumors).\textsuperscript{317,329} For patients with stage II to IV malignant germ cell tumors, postoperative chemotherapy is recommended. Postoperative chemotherapy for 3 to 4 cycles with bleomycin/etoposide/platinum (BEP) (category 2B for 3 vs. 4 cycles) is recommended for: 1) embryonal or endodermal sinus tumors; 2) stages III to V dysgerminoma; or 3) stage I, grade 2 to 3, or stage II to IV immature teratoma.\textsuperscript{318,331-333} If considering the use of bleomycin, pulmonary function tests are recommended.\textsuperscript{318,319} A 3-week BEP regimen may be useful in good-risk or stage 1 patients; the Memorial Sloan Kettering criteria can be used to identify good-risk tumors.\textsuperscript{327,334-337} In select patients with stage IB to III dysgerminoma for whom minimizing toxicity is critical, 3 courses of etoposide/carboplatin can be used (carboplatin 400 mg/m² [AUC =5–6] on day 1 plus etoposide 120 mg/m² on days 1–3 every 4 weeks for 3 courses).\textsuperscript{338} Dose reductions or delays are not recommended even in the setting of neutropenia.

Patients achieving a complete clinical response after chemotherapy should be observed clinically every 2 to 4 months with AFP and beta-HCG levels (if initially elevated) for 2 years. For those with abnormal markers and definitive recurrent disease, options (category 2B) include: 1) high-dose chemotherapy; or 2) consider additional chemotherapy (see Acceptable Recurrence Therapies in the NCCN Guidelines for Less Common Ovarian Histopathologies). Referral of these patients to a tertiary care center for potentially curative therapy is strongly recommended. Surveillance recommendations for germ cell tumors (which are based on the SGO recommendations) are described in the algorithm (see Surveillance for Germ Cell and Sex Cord-Stromal Tumors in the NCCN Guidelines for Less Common Ovarian Histopathologies).\textsuperscript{228} Several case reports suggest that patients who have received chemotherapy for germ cell tumors may later present with growing teratoma syndrome.\textsuperscript{339-342}

Residual or Recurrent Disease

For patients having radiographic evidence of residual tumor (after surgery and chemotherapy) but with normal AFP and beta-HCG, consider surgical resection of the tumor; observation is also an option. Further options depend on which findings are present: residual tumor, benign teratoma, or necrotic tissue (see Recurrent/Persistent Disease for Malignant Germ Cell Tumors in the NCCN Guidelines for Less Common Ovarian Histopathologies). For patients with definitive residual disease and with persistently elevated AFP and/or beta-HCG after first-line chemotherapy, recommendations include TIP (paclitaxel, ifosfamide, cisplatin)\textsuperscript{343} or high-dose chemotherapy with stem cell support. Referral to a tertiary care center for potentially curative treatment is strongly recommended.\textsuperscript{344} Observation is an option (category 2B) for patients with residual malignancy after surgical resection of residual masses; this is an area of continued study and controversy.\textsuperscript{317} Others may recommend further chemotherapy (category 2B). There are small series but no major trials in adult patients. Clinical judgment should be used regarding the frequency of imaging.\textsuperscript{345}

Patients with recurrent or residual disease after multiple chemotherapeutic regimens for whom no curative options are considered possible may be treated with a recurrence modality (see

---

Version 3.2014, 05/09/14 © National Comprehensive Cancer Network, Inc. 2014, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-19
Acceptable Recurrence Therapies for Malignant Germ Cell Tumors in the NCCN Guidelines for Less Common Ovarian Histopathologies, including TIP, VAC (vincristine, dactinomycin, cyclophosphamide), VeIP (vinblastine, ifosfamide, cisplatin), VIP (etoposide, ifosfamide, cisplatin), cisplatin/etoposide, docetaxel/carboplatin, paclitaxel/carboplatin, paclitaxel/gemcitabine, paclitaxel/ifosfamide, docetaxel, paclitaxel, high-dose chemotherapy, RT, or supportive care only.344,346-350

Combination chemotherapy is not recommended for patients with recurrent or residual disease who have no curative options. These recurrence regimens (see Acceptable Recurrence Therapies for Malignant Germ Cell Tumors in the NCCN Guidelines for Less Common Ovarian Histopathologies) are not generalizable for all of the uncommon histology tumors; therefore, patients should be referred to tertiary care institutions for treatment.

Malignant Sex Cord-Stromal Tumors

Malignant stromal tumors are rare and include granulosa cell tumors (most common), granulosa-theca tumors, and Sertoli-Leydig cell tumors; they are typically associated with a good prognosis.351 Most patients with granulosa tumors present with early-stage disease.352 It is important to determine whether the sex cord-stromal tumor is benign or malignant (see Sex Cord Stromal Tumors—WHO Histologic Classification in the NCCN Guidelines for Less Common Ovarian Histopathologies).353 The staging system for ovarian and primary peritoneal cancer is also used for sex cord-stromal tumors (see Table 1).

Patients with stage IA or IC sex cord-stromal tumors desiring to preserve their fertility should be treated with fertility-sparing surgery with complete staging.352,354,355 Although complete staging is recommended for all other patients, lymphadenectomy may be omitted.356 Patients who choose fertility-sparing surgery should be monitored by ultrasound examinations if necessary; completion surgery (category 2B) should be considered after finishing childbearing.

For patients with high-risk stage I tumors (tumor rupture, stage 1C, poorly differentiated tumor, tumor size >10–15 cm357), recommendations (all are category 2B) include observation or consideration of platinum-based chemotherapy.358 Those with surgical findings of low-risk stage I tumor (ie, without high-risk features) should be observed. For patients with granulosa cell tumors who are being observed, inhibin levels can be followed if they were initially elevated (category 2B). For patients with stage II to IV tumors, recommended options (all are category 2B) include RT for limited disease or platinum-based chemotherapy (BEP or paclitaxel/carboplatin regimens are preferred).359,360

Surveillance recommendations for sex cord-stromal tumors are provided in the algorithm, which are based on the SGO recommendations (see Surveillance for Germ Cell and Sex Cord-Stromal Tumors in the NCCN Guidelines for Less Common Ovarian Histopathologies).228 Prolonged surveillance is recommended for granulosa cell tumors, because they can recur years later (eg, 30 years).325,351,361 For patients with stage II to IV tumors who subsequently have a clinical relapse, options include a clinical trial or recurrence therapy (see Acceptable Recurrence Therapies for Malignant Sex Cord-Stromal Tumors in the NCCN Guidelines for Less Common Ovarian Histopathologies).351,361,362 Note that bevacizumab or leuprolide may be considered for patients with recurrent granulosa cell tumors.362,363 Secondary cytoreductive surgery may also be considered.

Carcinosarcomas (Malignant Mixed Müllerian Tumors)

MMMTs are rare tumors with a poor prognosis.364-366 Most pathologists now consider MMMTs to be a variant of poor risk, poorly differentiated
epithelial ovarian cancer (metaplastic carcinoma). Patients with MMMTs are not candidates for fertility-sparing surgery regardless of age. The staging system for ovarian and primary peritoneal cancer is also used for MMMTs (see Table 1). The characteristic pathologic hallmark of typical epithelial ovarian cancer is the identification of peritoneal implants, which microscopically and/or macroscopically invade the peritoneum. Ovarian LMP tumor has the visual appearance of peritoneal carcinomatosis. However, microscopic evaluation fails to reveal evidence of frank invasion by the tumor nodules, although rarely invasive implants (which continue to be consistent with the diagnosis of LMP lesions) can be identified microscopically by the pathologist. Some investigators feel that the appearance of invasive implants on the peritoneal surfaces in patients with ovarian LMP tumors portends a less favorable prognosis; therefore, postoperative chemotherapy (category 2B) with the same regimens used for epithelial ovarian cancer) can be considered for these patients (see Primary Treatment for Ovarian Low Malignant Potential Tumors). However, the benefit of chemotherapy, either IP or IV, is controversial in ovarian LMP tumors. The significance of invasive implants remains under investigation. Observation is an option for all patients although it may be a category 2B recommendation depending on the setting (see Primary Treatment for Ovarian Low Malignant Potential Tumors).
observation is one of several possible approaches. Patients with an LMP lesion who desire to maintain their fertility may undergo surgery limited to a USO (preserving the uterus, contralateral ovary, and contralateral fallopian tube) at the time of comprehensive staging. If the patient does not desire fertility-sparing surgery, observation or standard ovarian cancer debulking surgery is recommended. However, data do not show increased survival with lymphadenectomy and omentectomy for LMP, although upstaging does occur.

For patients with known LMP disease who had incomplete previous surgery and/or were incompletely staged at the time of their initial laparotomy, recommendations depend on whether invasive implants are present and whether fertility preservation is desired (see Primary Treatment for Incomplete Previous Surgery in the NCCN Guidelines for Ovarian Low Malignant Potential Tumors). Patients who want to preserve their fertility should have comprehensive fertility-sparing surgical staging (category 2B) if not previously done.

Follow-up

Treatment recommendations after comprehensive staging depend on the presence or absence of invasive implants. The initial therapeutic approach for patients having invasive implants may include observation or, alternatively, patients may be treated with the same chemotherapeutic regimens used for epithelial ovarian cancer (category 2B for postoperative chemotherapy) (see Primary Treatment in the NCCN Guidelines for Ovarian Low Malignant Potential Tumors). Patients with no invasive implants should be observed and monitored (see Monitoring/Follow-Up in the NCCN Guidelines for Ovarian Low Malignant Potential Tumors). Patients who chose fertility-sparing surgery should be monitored by ultrasound examinations if necessary.

After childbearing is completed, completion surgery should be considered (category 2B).

Relapse

At the time of clinical relapse, a surgical evaluation and debulking are recommended if appropriate. Patients who have invasive disease at this time may be treated with epithelial ovarian cancer regimens (category 2B) (see Primary Chemotherapy/Primary Adjuvant Therapy in the NCCN Guidelines for Ovarian Low Malignant Potential Tumors); those without invasive implants should be observed. Chemotherapy (either IP or IV) has not been shown to be beneficial in treatment of ovarian LMP tumors.

Recommended Readings


Ovarian Cancer


References marked with this symbol provided the basis for the algorithms.
References


17. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for...


Ovarian Cancer


105. Van Gorp T, Caduff I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of


232. Rustin GJ, van der Burg ME, MRC Obo, EORTC Collaborators. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) [abstract]. J Clin Oncol 2009;27(Suppl 18S):Abstract 1. Available at: [http://meeting.asco.org/cgi/content/abstract/27/18S/1](http://meeting.asco.org/cgi/content/abstract/27/18S/1).


261. Rose PG. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. Int J Gynecol Cancer


274. Matsumoto K, Katsumata N, Yamanaka Y, et al. The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxane-


331. Brown J, Shvartsman HS, Deavers MT, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the


